

1 **Worldwide emergence of resistance to antifungal drugs**
2 **challenges human health and food security**

3

4 Matthew C. Fisher^{1*}, Nichola J. Hawkins², Dominique Sanglard³ and Sarah J. Gurr^{4*}

5

6 ^{1*}Matthew C. Fisher, Faculty of Medicine, School of Public Health, Imperial College London,
7 W2 1PG, UK

8 ²Nichola J. Hawkins, Biointeractions and Crop Protection, Rothamsted Research, Harpenden,
9 AL5 2JQ, UK

10 ³Dominique Sanglard, Institute of Microbiology, University of Lausanne and University
11 Hospital, Lausanne CH-1011, Switzerland

12 ^{4*}Sarah J. Gurr, BioSciences, University of Exeter, EX4 4QD, UK and Utrecht University,
13 Padualaan 8, The Netherlands

14

15 *Corresponding authors: Matthew Fisher (matthew.fisher@imperial.ac.uk) and Sarah Gurr
16 (s.j.gurr@exeter.ac.uk)

17

18 **Short title:** Fungicide resistance threatens health and crops

19

20 **One sentence summary:** Emerging resistance to antifungal drugs and fungicides is
21 compromising our ability to treat fungal diseases in humans and in crops, necessitating new
22 approaches to control endemic and emerging infections.

23

24

25 **Abstract**

26 We are witnessing an unprecedented rise in the rate of emergence of pathogenic fungi that
27 are resistant to the limited number of commonly used antifungal agents. For example, the
28 azoles are used for human and animal healthcare, for plant crop protection and in
29 antifouling coatings and timber preservation. The ubiquity and dual-use of azoles has
30 hastened the independent evolution of resistance in many environments. One consequence
31 is an increasing risk emerging from naturally occurring 'opportunistic' and antifungal
32 resistant pathogens, which challenge human healthcare. To avoid a global collapse in our
33 ability to control fungal infections and to avoid critical failures in healthcare and food
34 security, we must improve our stewardship of extant chemicals, promote novel antifungal
35 discovery and leverage emerging technologies for alternative solutions.

36

37 **Introduction**

38 The rapid emergence of multidrug resistant pathogenic fungi and the better-publicised
39 threat of antibiotic resistant bacteria both pose a considerable threat to disease control
40 across diverse anthropogenic systems. These microbes respond adroitly to human-induced
41 natural selection through chemical treatments, and nimbly hijack human globalisation
42 pathways (1), so disseminating the problems world-wide. Today, crop-destroying fungi
43 account for perennial yield losses of around 20% worldwide, with a further 10% loss post-
44 harvest. Fungal impacts on human health are currently spiralling and global mortality
45 caused by fungal diseases now exceeds that for malaria, or breast cancer, and is comparable
46 to tuberculosis and HIV (2). These infections have, hitherto, been greatly neglected relative
47 to other classes of infectious disease, despite occurring in more than a quarter of the
48 world's population.

49 The first antifungal chemicals used in human healthcare, Nystatin and the polyenes, were
50 discovered in the 1950s, whilst copper and sulphur fungicides were first used to control crop
51 disease over 150 years ago. Today, systemic fungicides and antifungals are frontline
52 treatments for fungal diseases in both humans and plants. This control can, however, be
53 ephemeral as a result of the rapid development of resistance against the chemicals. Fungi
54 have highly plastic genomes and reproduce rapidly producing large populations. The

55 combination of these properties quickly generates variants, selected for resistance. In plant
56 pathogens, the pace of breakdown is enhanced by monoculture cropping practices, as large
57 swathes of genetically uniform crops provide ideal feeding and breeding grounds for the
58 rapid emergence of fungicide-resistant variants. In humans, long periods of prophylactic
59 treatment in at-risk patients can similarly lead to the emergence of antifungal resistance (3).
60 Resistance to all licensed systemic antifungals has been documented in clinical pathogens,
61 although the rate of emergence varies between drug classes (Fig. 1) (3). Likewise, despite
62 the wider range of fungicides licenced for use in agriculture, resistance to each main class of
63 fungicides has emerged in some major pathogens (Fig. 1). This threat is exacerbated by the
64 additional threat of withdrawal of some chemical classes due to regulatory changes in, for
65 example the EU.



66 figure_1.ai

67 **Antifungals for the treatment of fungal diseases in the clinic and the field**

68 The chemical control of fungal pathogens that cause diseases in animals and crops has
69 progressed from the use of inorganic chemistries, through organic surface protectant
70 chemistries, to systemic-acting fungicides. There are approximately nine-fold more
71 antifungal compounds available to control crop diseases than to treat systemic animal
72 infections. Licenced treatments in humans are limited to four frontline classes of drugs (Fig.
73 1). The polyenes (such as amphotericin B) disrupt the structure of cell membranes by
74 sequestering the fungal membrane sterol ergosterol. The pyrimidine analogue 5-
75 fluorocytosine (5-FC) blocks pyrimidine metabolism and DNA synthesis. The newest class of
76 antifungals, the echinocandins, inhibit (1-3)- β -D glucan synthase and disrupt cell wall
77 biosynthesis. The fourth and most widely used class of fungicides - the azoles, block
78 ergosterol biosynthesis through inhibition of lanosterol 14- α -demethylase. Most fungicides
79 for crop disease target mitochondrial function, the cytoskeleton, or ergosterol biosynthetic
80 pathways (Fig. 1), although some specialist chemistries, such as the aza-naphthalenes for
81 powdery mildew control, target other pathways.

82 It is important to highlight that the azoles are the dominant chemistry in the treatment of
83 fungal infections in crops, humans and livestock, with 5 licenced clinical azole antifungals
84 and 31 for crop protection.

85 **Parallel drivers of fungicide resistance in the clinic and the field**

86 Human population growth, urbanisation and economic prosperity have fuelled demands for
87 increasing quantity and variety of food. Intensive agriculture has too often responded to this
88 demand with crops bred for maximum productivity under the protection of broad-scale
89 pesticide applications, inadvertently breeding out the plants' own defences. In parallel, the
90 number of humans at risk from fungal infections is rising rapidly, as susceptible populations
91 increase, either through age, medical interventions or HIV infection. Medical advances
92 leading to greater initial survival of cancer or organ transplants can unfortunately leave
93 patients susceptible to secondary attack from opportunistic fungi, leading to increasing use
94 of antifungal drugs in clinical practice. Consequently, we are now witnessing an
95 unprecedented worldwide increase in antifungal resistance, through both space and time
96 (Fig. 2; Supp Table1).



97 Figure 2 lin.ai

98 The main drivers that underpin these changes are explored in Fig. 3. The global movement
99 of people and trade in produce has hastened the free-flow of fungal pathogens from
100 country to country, bringing new pathogens into contact with naïve hosts (1). In the clinical
101 setting, new species of multidrug resistant pathogenic fungi are emerging. *Candida auris*,
102 first described in Japan in 2009 following isolation from a patient's ear, is responsible for a
103 rapidly increasing number of hospital-acquired invasive infections around the world (4). This
104 fungus is now resistant to all clinical antifungals (5) and presents a particular threat to
105 intensive-care units since it can survive normal decontamination protocols (6). The
106 emergence of resistance in *Candida glabrata* has coincided with this species becoming the
107 predominant bloodstream pathogen recovered from patients, due largely to the increasing
108 prophylactic use of echinocandins and azoles (7). There is also a growing threat from
109 filamentous pathogenic fungi which are intrinsically-resistant to a broad range of
110 antifungals; for example *Aspergillus terreus* (8), *Scedosporium spp.* (9), *Fusarium spp* (10)
111 and members of the mucorales (11). Simultaneously, we are witnessing the relentless

112 emergence of new races of plant-infecting fungi able to overcome both host defences and
113 chemical treatments (12), as well as the evolution of these traits in existing major pathogens
114 (13)(14). The first case of resistance against the MBCs was reported in 1969 (15) and now
115 MBC resistance is known in over 90 plant pathogens (16). Azole resistance in a plant
116 pathogen was first reported in 1981 (17), but azole resistance is generally partial, in contrast
117 to the complete control failures seen for MBCs (18). QoI resistance was reported in field
118 trials even before commercial introduction, and in wider field populations within two years
119 of release (19). A new generation of SDHI fungicides has been introduced from 2007, but by
120 2017, resistant field isolates had been found in 17 pathogen species (20). Pathogens with
121 resistance against MBCs, azole, QoIs and SDHIs include the major wheat pathogen
122 *Zymoseptoria tritici*, banana black sigatoka pathogen *Mycosphaerella fijiensis*, cereal
123 powdery mildews *Blumeria graminis*, the emerging barley pathogen *Ramularia collo-cygni*
124 and the apple scab fungus *Venturia inaequalis*. In *Botrytis cinerea* (a generalist pathogen
125 that causes grey mould, particularly on soft fruits), resistance has been reported against 15
126 different classes of systemic and protectant fungicides (21).



figure3.ai

127

128 **Parallel evolution of resistance mechanisms in the clinic and the field**

129 The strong and highly specific selective pressure exerted on fungi by single-site-inhibiting
130 fungicides has resulted in similar adaptations arising over time in disparate fungal species.
131 Indeed, this parallel evolution extends across clinical and plant pathogenic fungi, with the
132 same key resistance mechanisms occurring independently in both.

133 Mutations resulting in conformation changes to the drug target site constitute the most
134 common resistance mechanism in pathogenic fungi. They have been reported in candidin-
135 resistant clinical pathogens; MBC, QoI and SDHI-resistant plant pathogens; and azole-
136 resistant strains in field and clinic. A single mutation, G143A in cytochrome *b*, has emerged
137 in the field in over 20 species under selection by QoIs (14). Moreover, the Y137F
138 substitution in CYP51 has been found in multiple plant pathogens with partial azole
139 resistance, and Y132F occurs at the equivalent residue in *C. albicans* (22). Promoter changes
140 resulting in upregulation of the fungicide target are also common across clinical and plant
141 pathogenic fungi (23). In *A. fumigatus*, tandem repeats in the *CYP51A* promoter region

142 occur together with downstream SNPs in the coding region, conferring a multi-azole
143 resistance phenotype (24).

144 A third resistance mechanism involves reducing intracellular drug accumulation, through
145 upregulation of efflux pumps. The upregulated efflux pumps may be ABC transporters or
146 major facilitators, and their upregulation may result from promoter insertions or
147 transcription factor gain-of-function mutations (3, 25).

148 Further resistance mechanisms have so far been identified only in clinical pathogens.
149 Activation of stress response pathways by Hsp90 can unleash cryptic diversity, potentiating
150 the evolution of resistance to azoles, echinocandins and polyenes in *Candida* and *Aspergillus*
151 species (26). Structural genomic plasticity can result in resistance, with chromosome arm
152 duplications leading to efflux pump and target-site overexpression in *C. albicans* (25, 27).
153 Hypermutator strains of *C. glabrata* and *Cryptococcus* were recently reported, with the
154 potential to evolve rapidly in response to host and drug selection (28, 29).

155

156 **Dual-use of azoles in the clinic and the field**

157 The azoles are the most widely-deployed class of fungicides in crop protection, totalling, for
158 example, over 26% of all fungicides across the European Union (30). Azoles are also frontline
159 drugs that protect humans and animals against pathogenic fungi. However, dual-use may
160 have promoted azole resistance in an opportunistic pathogen of humans, threatening our
161 ability to use this important class of drugs (30, 31). The saprotroph *Aspergillus fumigatus*
162 colonises decaying vegetation in fields, forests and compost heaps and also infects
163 immunocompromised humans. Multi-azole-resistant *A. fumigatus* has been recovered from
164 both environmental and clinical samples across multiple continents. In the Netherlands,
165 over 25% of *Aspergillus* infections carry azole-resistance alleles. Azoles are increasingly
166 failing as frontline therapies, with associated patient mortality approaching 100% (32).
167 Population genomic analyses have shown that azole-resistant alleles in *A. fumigatus* are
168 associated with selective sweeps in regions of high azole-usage such as India (33).
169 Moreover, recombination also occurs, generating new combinations of azole-resistance
170 alleles (33). Investigations are now underway to assess the relative contributions of clinical
171 and environmental selection to azole-resistant *A. fumigatus*, and to identify the most

172 problematic environmental applications of azoles. The potential conflict between the level
173 of agricultural use and the durability of clinical effectiveness of azoles highlights how limited
174 the antifungal toolbox is, where neither “side” can afford to lose a mode of action. Medicine
175 and food security are both vital to human health (34), and both fields are in urgent need of
176 a wider range of options to control fungal diseases.

177
178 However, most cases of fungicide and antifungal resistance across field and clinic appear to
179 have arisen by the repeated independent evolution of resistance to successive fungicides
180 within numerous fungal species. This is where evolution of antifungal resistance differs
181 fundamentally from antibacterial resistance, which is frequently transferred between
182 animals and humans via the ‘mobilome’ of plasmids and phage (35). There is some evidence
183 of horizontal gene transfer among fungi, (36) but this occurs on longer timescales than gene
184 transfer among bacteria and the dynamics of resistance arising by this route is thus far
185 negligible.

186

187 **Prospects for diversifying the toolbox for fungal control**

188 To counter the escalating risks of fungal disease we need to discover antifungal chemistries
189 with novel modes of action, hinder the emergence of resistance in extant chemistries by
190 better stewardship, and develop novel disease control strategies to avoid over-reliance on
191 fungicides:

192 **Development of novel antifungals:** The rate of emergence of fungicide resistance (Fig. 2) is
193 greater than the pace of fungicide discovery, and the long registration process for new
194 compounds adds further delays. This parallels the situation for antibiotics. There is thus a
195 need for increased research activity to develop new antifungal drugs (37). Recently, there
196 has been significant progress in this field, with at least 11 antifungals in Phase I-II clinical
197 trials and at least 2 in the AgChem pipeline. Several of these are derivatives of commonly
198 used antifungal chemicals, such as ergosterol biosynthesis and cell wall biosynthesis
199 inhibitors, engineered for higher efficacy, whilst others have new modes of action. Further,
200 combining molecular modelling, combinatorial chemistry and high-throughput screening has
201 the potential to develop chemistries with reduced resistance risk due to the complexity of
202 the molecular changes required (38).

203 **Stewardship of existing compounds:** Robust global strategies are needed to slow the
204 development of antifungal resistance. Combining different modes of action either in
205 mixtures, or as alternating treatments, may slow the emergence of resistance. A clinical trial
206 has shown that combinations of fluconazole, flucytosine and amphotericin-B can effectively
207 treat HIV-associated cryptococcal meningitis (39). In agriculture, mixtures of fungicides with
208 different modes of action are already widely recommended (40), with some formulations
209 only available as mixed products. Where target-site mutations confer high levels of
210 resistance lower doses of antifungals should be favoured (41, 42). However, this results in a
211 trade-off between immediate effectiveness of treatment and slowing the selection of
212 resistance. There is also a need to improve molecular diagnostics, both for the identification
213 of fungal pathogens so antifungals can be used appropriately, and for the detection of
214 specific resistance-alleles as the monitoring of resistance is a vital part of stewardship (43).

215

216 **Integrated disease management:** To reduce our reliance on chemical control alone we must
217 develop more non-chemical control measures, to use where effective fungicides are no
218 longer available, or to use in combination with fungicides to reduce the selective pressure
219 on each component. In crops, the development of innate disease resistance through the
220 selection of major pathogen-resistant (R) alleles is widely used to breed disease resistant
221 cultivars. However, this approach is slow, with a 20 year lag from finding a suitable disease
222 resistance gene to releasing it in commercial lines. Marker-assisted breeding can speed up
223 the recombination of multiple disease resistance alleles, but still takes around a decade (44).
224 Transgene cloning or gene editing is faster still (*circa* 2 years), but no crops with transgenic
225 antifungal disease resistance have yet been released commercially. The high degree of
226 specificity between host and pathogen in major R genes (45) means pathogens can also
227 rapidly evolve to overcome this control measure. However, “evolution-smart” disease-
228 resistant crops with pyramided pathogen resistance genes or mosaic deployment of
229 resistant varieties may provide greater durability of disease control. Minor resistance genes
230 (r), such as the antifungal chitinases and glucanases, carry the advantage of broad spectrum
231 activity (46), but suffer the possible disadvantage of yield penalties as well as incomplete
232 protection. Further sources of genetic disease resistance can be found in the gene pools of
233 crop wild relatives, which may be introduced to modern crop varieties through introgression
234 or transgenesis (44).

235

236 In humans, advances in combination anti-retroviral therapy to halt HIV-AIDS progression,
237 gene therapies under development for cystic fibrosis, or tissue engineering for rejection-free
238 transplants, can reduce vulnerability to fungal infections in such patient cohorts. Also, the
239 first antifungal vaccine, against *C. albicans*, is undergoing clinical trials (47) and the use of
240 bioengineered T cells to augment host immunity is being explored (48). Finally, the
241 identification of human genetic biomarkers associated with susceptibility to fungal diseases,
242 for example *PTX3* SNPs and *A. fumigatus* (49), provides a new path to identify patient groups
243 in which antifungal treatments could be reduced.

244 The rapidly growing fields of synthetic biology and epigenomics are converging on antifungal
245 treatments using RNA interference (RNAi). Bidirectional cross-kingdom microRNA (miRNA)
246 trafficking between plants and fungi is being developed as a novel strategy to tackle
247 pathogens (50), such as *Botrytis cinerea* which uses miRNA virulence effectors to silence
248 host plant immune genes (51, 52). Current research avenues include identifying new targets
249 for RNAi; and, crucially, developing systems for the stable and targeted delivery of RNA
250 silencing, through genetic engineering of the host plant or exogenous application of
251 synthetic RNA (51-53). Whilst such approaches have not yet been utilised to treat fungal
252 infections in the clinic, the discovery and use of RNAi as a clinical antifungal approach
253 represents a potentially transformational approach to tackling human fungal infections.

254 **Conclusion**

255 In both fungi and bacteria, the emergence of resistance has outpaced the supply of new
256 antimicrobial compounds. There is an urgent need to increase the pipeline of new active
257 compounds, to improve anti-resistance stewardship of existing products, and to diversify our
258 control toolbox with the development of novel non-chemical control methods.

259

260 **Acknowledgements:** Professors Chris Thornton and Gero Steinberg for their critical
261 appraisal of the manuscript; Charlotte Gurr for infographics based on ideas by NJH; Alireza
262 Abdolrasouli for assistance with literature searches. Funding bodies; MCF was supported by
263 the Natural Environmental Research Council (NERC: NE/K014455/1) and the Medical
264 Research Council (MRC: MR/K000373/1): NJH through the BBSRC's Industrial Strategy

265 Challenge Fund (BBS/OS/CP/000001): DS by Swiss National Science Foundation (FN
266 301003A-172958) and SJG by BBSRC (BB/PO18335, awarded to Gero Steinberg and SJG)

267 **Author contributions:** MCF, NJH, DS, and SJG conceived and wrote the paper.

268

269

References

270

- 271 1. M. C. Fisher *et al.*, Emerging fungal threats to animal, plant and ecosystem health.
272 *Nature* **484**, 186-194 (2012).
- 273 2. G. D. Brown *et al.*, Hidden Killers: Human Fungal Infections. *Sci Transl Med* **4**, (2012).
- 274 3. N. Robbins, T. Caplan, L. E. Cowen, Molecular Evolution of Antifungal Drug
275 Resistance. *Annu Rev Microbiol* **71**, 753-775 (2017).
- 276 4. A. Chowdhary, C. Sharma, J. F. Meis, *Candida auris*: A rapidly emerging cause of
277 hospital-acquired multidrug-resistant fungal infections globally. *PLoS Pathog* **13**,
278 e1006290 (2017).
- 279 5. S. R. Lockhart *et al.*, Simultaneous Emergence of Multidrug-Resistant *Candida auris*
280 on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological
281 Analyses. *Clin Infect Dis* **64**, 134-140 (2017).
- 282 6. S. Schelenz *et al.*, First hospital outbreak of the globally emerging *Candida auris* in a
283 European hospital. *Antimicrob Resist Infect Control* **5**, 35 (2016).
- 284 7. B. D. Alexander *et al.*, Increasing Echinocandin Resistance in *Candida glabrata*:
285 Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum
286 Inhibitory Concentrations. *Clin Infect Dis* **56**, 1724-1732 (2013).
- 287 8. R. Hachem *et al.*, Invasive aspergillosis caused by *Aspergillus terreus*: an emerging
288 opportunistic infection with poor outcome independent of azole therapy. *The*
289 *Journal of antimicrobial chemotherapy* **69**, 3148-3155 (2014).
- 290 9. M. Lackner *et al.*, Species-specific antifungal susceptibility patterns of *Scedosporium*
291 and *Pseudallescheria* species. *Antimicrob Agents Chemother* **56**, 2635-2642 (2012).
- 292 10. A. M. Al-Hatmi, F. Hagen, S. B. Menken, J. F. Meis, G. S. de Hoog, Global molecular
293 epidemiology and genetic diversity of *Fusarium*, a significant emerging group of
294 human opportunists from 1958 to 2015. *Emerg Microbes Infect* **5**, e124 (2016).

- 295 11. M. Slavin *et al.*, Invasive infections due to filamentous fungi other than *Aspergillus*:
296 epidemiology and determinants of mortality. *Clinical microbiology and infection : the*
297 *official publication of the European Society of Clinical Microbiology and Infectious*
298 *Diseases* **21**, 490 e491-410 (2015).
- 299 12. M. T. Islam *et al.*, Emergence of wheat blast in Bangladesh was caused by a South
300 American lineage of *Magnaporthe oryzae*. *Bmc Biol* **14**, (2016).
- 301 13. M. S. Hovmoller *et al.*, Replacement of the European wheat yellow rust population
302 by new races from the centre of diversity in the near-Himalayan region. *Plant*
303 *Pathology* **65**, 402-411 (2016).
- 304 14. J. A. Lucas, N. J. Hawkins, B. A. Fraaije, The evolution of fungicide resistance.
305 *Advances in Applied Microbiology* **90**, 29-92 (2015).
- 306 15. W. T. Schroeder, R. Provvidenti, Resistance to Benomyl in powdery mildew of
307 cucurbits. *Plant Disease Reporter* **53**, 271-275 (1969).
- 308 16. N. J. Hawkins, B. A. Fraaije, Predicting resistance by mutagenesis: Lessons from 45
309 Years of MBC Resistance. *Frontiers in Microbiology* **7**, 1814 (2016).
- 310 17. J. T. Fletcher, M. S. Wolfe, in *British Crop Protection Conference- Pests and Diseases*.
311 (BCPC, Brighton, 1981), vol. 2, pp. 633-640.
- 312 18. H. Cools, B. Fraaije, Are azole fungicides losing ground against Septoria wheat
313 disease? Resistance mechanisms in *Mycosphaerella graminicola*. *Pest Management*
314 *Science* **64**, 681-684 (2008).
- 315 19. S. P. Heaney, A. Hall, S. A. Davies, G. Olaya, paper presented at the The BCPC
316 Conference - Pests and Diseases 2000, .
- 317 20. Fungicide Resistance Action Committee. " List of plant pathogenic organisms
318 resistant to disease control agents" <http://www.frac.info>; Retrieved 23/01/2018
319 (2017).
- 320 21. M. Hahn, The rising threat of fungicide resistance in plant pathogenic fungi: Botrytis
321 as a case study. *J Chem Biol* **7**, 133-141 (2014).
- 322 22. H. J. Cools, B. A. Fraaije, Are azole fungicides losing ground against Septoria wheat
323 disease? Resistance mechanisms in *Mycosphaerella graminicola*. *Pest Manag Sci* **64**,
324 681-684 (2008).

- 325 23. H. Hamamoto *et al.*, Tandem repeat of a transcriptional enhancer upstream of the
326 sterol 14 alpha-demethylase gene (CYP51) in *Penicillium digitatum*. *Appl Environ*
327 *Microb* **66**, 3421-3426 (2000).
- 328 24. E. Snelders *et al.*, The structure-function relationship of the *Aspergillus fumigatus*
329 cyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole
330 resistance. *Fungal Genet Biol* **48**, 1062-1070 (2011).
- 331 25. N. J. Hawkins *et al.*, Paralog re-emergence: A novel, historically contingent
332 mechanism in the evolution of antimicrobial resistance. *Mol. Biol. Evol.* **31**, 1793-
333 1802 (2014).
- 334 26. L. E. Cowen, S. Lindquist, Hsp90 potentiates the rapid evolution of new traits: drug
335 resistance in diverse fungi. *Science* **309**, 2185-2189 (2005).
- 336 27. A. Selmecki, M. Gerami-Nejad, C. Paulson, A. Forche, J. Berman, An isochromosome
337 confers drug resistance *in vivo* by amplification of two genes, ERG11 and TAC1. *Mol*
338 *Microbiol* **68**, 624-641 (2008).
- 339 28. J. Rhodes *et al.*, A population genomics approach to assessing the genetic basis of
340 within-host microevolution underlying recurrent Cryptococcal meningitis infection.
341 *G3* **7**, 1165-1176 (2017).
- 342 29. K. R. Healey *et al.*, Prevalent mutator genotype identified in fungal pathogen *Candida*
343 *glabrata* promotes multi-drug resistance. *Nat Commun* **7**, 11128 (2016).
- 344 30. European Centers for Disease Control. "Risk assessment on the impact of
345 environmental usage of triazoles on the development and spread of resistance to
346 medical triazoles in *Aspergillus* species" (Stockholm, 2013).
- 347 31. J. F. Meis, A. Chowdhary, J. L. Rhodes, M. C. Fisher, P. E. Verweij, Clinical implications
348 of globally emerging azole resistance in *Aspergillus fumigatus*. *Philos Trans R Soc*
349 *Lond B Biol Sci* **371**, (2016).
- 350 32. J. van Paassen, A. Russcher, A. W. in t'Veld-van Wingerden, P. E. Verweij, E. J.
351 Kuijper, Emerging aspergillosis by azole-resistant *Aspergillus fumigatus* at an
352 intensive care unit in the Netherlands, 2010 to 2013. *Eurosurveillance* **21**, 16-24
353 (2016).
- 354 33. A. Abdolrasouli *et al.*, Genomic context of azole resistance mutations in *Aspergillus*
355 *fumigatus* determined using whole-genome sequencing. *Mbio* **6**, e00536-00515
356 (2015).

- 357 34. C. Swanton, H. Mashhadi, K. Solomon, M. Afifi, S. Duke, Similarities between the
358 discovery and regulation of pharmaceuticals and pesticides: in support of a better
359 understanding of the risks and benefits of each. *Pest Management Science* **67**, 790-
360 797 (2011).
- 361 35. T. A. Richards *et al.*, Horizontal gene transfer facilitated the evolution of plant
362 parasitic mechanisms in the oomycetes. *P Natl Acad Sci USA* **108**, 15258-15263
363 (2011).
- 364 36. J. A. Perry, G. D. Wright, The antibiotic resistance "mobilome": searching for the link
365 between environment and clinic. *Front Microbiol* **4**, (2013).
- 366 37. D. W. Denning, M. J. Bromley, How to bolster the antifungal pipeline. *Science* **347**,
367 1414-1416 (2015).
- 368 38. J. L. Nishikawa *et al.*, Inhibiting fungal multidrug resistance by disrupting an
369 activator-mediator interaction. *Nature* **530**, 485+ (2016).
- 370 39. M. Molefi *et al.*, AMBITION-cm: intermittent high dose Ambisome on a high dose
371 fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan
372 Africa: study protocol for a randomized controlled trial. *Trials* **16**, 276 (2015).
- 373 40. H. Dooley, M. W. Shaw, J. Spink, S. Kildea, Effect of azole fungicide mixtures,
374 alternations and dose on azole sensitivity in the wheat pathogen *Zymoseptoria tritici*.
375 *Plant Pathology* **65**, 124-136 (2016).
- 376 41. F. van den Bosch, N. Paveley, M. Shaw, P. Hobbelen, R. Oliver, The dose rate debate:
377 does the risk of fungicide resistance increase or decrease with dose? *Plant Pathology*
378 **60**, 597-606 (2011).
- 379 42. A. Mikaberidze, N. Paveley, S. Bonhoeffer, F. van den Bosch, Emergence of resistance
380 to fungicides: The role of fungicide dose. *Phytopathology* **107**, 545-560 (2017).
- 381 43. B. Barres *et al.*, Trends and challenges in pesticide resistance detection. *Trends Plant*
382 *Sci* **21**, 834-853 (2016).
- 383 44. S. Ashkani *et al.*, Molecular breeding strategy and challenges towards improvement
384 of blast disease resistance in rice crop. *Front Plant Sci* **6**, (2015).
- 385 45. S. J. Gurr, P. J. Rushton, Engineering plants with increased disease resistance: what
386 are we going to express? *Trends Biotechnol* **23**, 275-282 (2005).

- 387 46. H. F. Eissa *et al.*, Developing transgenic wheat to encounter rusts and powdery
388 mildew by overexpressing barley chi26 gene for fungal resistance. *Plant Methods* **13**,
389 (2017).
- 390 47. J. Edwards, Fungal cell wall vaccines: an update. *Journal of Medical Microbiology* **61**,
391 895-903 (2012).
- 392 48. P. R. Kumaresan *et al.*, Bioengineering T cells to target carbohydrate to treat
393 opportunistic fungal infection. *Proc Natl Acad Sci U S A* **111**, 10660-10665 (2014).
- 394 49. C. Cunha *et al.*, Genetic PTX3 deficiency and aspergillosis in stem-cell
395 transplantation. *N Engl J Med* **370**, 421-432 (2014).
- 396 50. M. Z. Ratajczak, J. Ratajczak, Horizontal transfer of RNA and proteins between cells
397 by extracellular microvesicles: 14 years later. *Clin Transl Med* **5**, (2016).
- 398 51. A. Weiberg *et al.*, Fungal small RNAs suppress plant immunity by hijacking host RNA
399 interference pathways. *Science* **342**, 118-123 (2013).
- 400 52. M. Wang *et al.*, Bidirectional cross-kingdom RNAi and fungal uptake of external RNAs
401 confer plant protection. *Nat Plants* **2**, 16151 (2016).
- 402 53. L. Kudsiova *et al.*, Delivery of siRNA using ternary complexes containing branched
403 cationic peptides: the role of peptide sequence, branching and targeting. *Mol Biosyst*
404 **12**, 934-951 (2016).
- 405
- 406

407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438

Supplementary data references:

References in S Table1

54. D. W. Denning *et al.*, Itraconazole resistance in *Aspergillus fumigatus*. *Antimicrob Agents Chemother* **41**, 1364-1368 (1997).
55. E. Chryssanthou, *In vitro* susceptibility of respiratory isolates of *Aspergillus* species to itraconazole and amphotericin B. acquired resistance to itraconazole. *Scandinavian journal of infectious diseases* **29**, 509-512 (1997).
56. E. Snelders *et al.*, Emergence of azole resistance in *Aspergillus fumigatus* and spread of a single resistance mechanism. *PLoS medicine* **5**, e219 (2008).
57. C. Lazzarini *et al.*, Azole Resistance in *Aspergillus fumigatus* Clinical Isolates from an Italian Culture Collection. *Antimicrob Agents Chemother* **60**, 682-685 (2016).
58. M. Tashiro *et al.*, Antifungal susceptibilities of *Aspergillus fumigatus* clinical isolates obtained in Nagasaki, Japan. *Antimicrob Agents Chemother* **56**, 584-587 (2012).
59. S. J. Howard *et al.*, Frequency and evolution of Azole resistance in *Aspergillus fumigatus* associated with treatment failure. *Emerging infectious diseases* **15**, 1068-1076 (2009).
60. E. Dannaoui *et al.*, *In-vitro* susceptibility of *Aspergillus* spp. isolates to amphotericin B and itraconazole. *The Journal of antimicrobial chemotherapy* **44**, 553-555 (1999).
61. G. E. Ozmerdiven *et al.*, First determination of azole resistance in *Aspergillus fumigatus* strains carrying the TR34/L98H mutations in Turkey. *Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy* **21**, 581-586 (2015).
62. A. Warris *et al.*, Molecular epidemiology of *Aspergillus fumigatus* isolates recovered from water, air, and patients shows two clusters of genetically distinct strains. *J Clin Microbiol* **41**, 4101-4106 (2003).
63. T. Pelaez *et al.*, First detection of *Aspergillus fumigatus* azole-resistant strain due to Cyp51A TR46/Y121F/T289A in an azole-naive patient in Spain. *New microbes and new infections* **6**, 33-34 (2015).
64. S. Seyedmousavi *et al.*, Azole-resistant *Aspergillus fumigatus*, Iran. *Emerging infectious diseases* **19**, 832-834 (2013).

- 439 65. S. E. Kidd, E. Goeman, J. F. Meis, M. A. Slavin, P. E. Verweij, Multi-triazole-resistant
440 *Aspergillus fumigatus* infections in Australia. *Mycoses* **58**, 350-355 (2015).
- 441 66. A. Chowdhary *et al.*, Isolation of multiple-triazole-resistant *Aspergillus fumigatus*
442 strains carrying the TR/L98H mutations in the *cyp51A* gene in India. *The Journal of*
443 *antimicrobial chemotherapy* **67**, 362-366 (2012).
- 444 67. E. Vermeulen *et al.*, Nationwide surveillance of azole resistance in *Aspergillus*
445 diseases. *Antimicrob Agents Chemother* **59**, 4569-4576 (2015).
- 446 68. U. Nawrot *et al.*, Detection of Polish clinical *Aspergillus fumigatus* isolates resistant
447 to triazoles. *Med Mycol* **56**, 121-124 (2018).
- 448 69. K. M. Astvad *et al.*, First detection of TR46/Y121F/T289A and TR34/L98H alterations
449 in *Aspergillus fumigatus* isolates from azole-naïve patients in Denmark despite
450 negative findings in the environment. *Antimicrob Agents Chemother* **58**, 5096-5101
451 (2014).
- 452 70. S. R. Lockhart *et al.*, Azole resistance in *Aspergillus fumigatus* isolates from the
453 ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the
454 *cyp51A* gene. *Antimicrob Agents Chemother* **55**, 4465-4468 (2011).
- 455 71. B. Belleste *et al.*, Acquired resistance to voriconazole and itraconazole in a patient
456 with pulmonary aspergilloma. *Med Mycol* **48**, 197-200 (2010).
- 457 72. O. Bader *et al.*, *cyp51A*-Based mechanisms of *Aspergillus fumigatus* azole drug
458 resistance present in clinical samples from Germany. *Antimicrob Agents Chemother*
459 **57**, 3513-3517 (2013).
- 460 73. C. J. Wu *et al.*, Azole-resistant *Aspergillus fumigatus* isolates carrying TR(34)/L98H
461 mutations in Taiwan. *Mycoses* **58**, 544-549 (2015).
- 462 74. S. Ahmad, L. Joseph, F. Hagen, J. F. Meis, Z. Khan, Concomitant occurrence of
463 itraconazole-resistant and -susceptible strains of *Aspergillus fumigatus* in routine
464 cultures. *The Journal of antimicrobial chemotherapy* **70**, 412-415 (2015).
- 465 75. A. Chowdhary *et al.*, Multi-azole-resistant *Aspergillus fumigatus* in the environment
466 in Tanzania. *Journal of Antimicrobial Chemotherapy* **69**, 2979-2983 (2014).
- 467 76. P. Le Pape, R. A. Lavergne, F. Morio, C. Alvarez-Moreno, Multiple fungicide-driven
468 alterations in Azole-resistant *Aspergillus fumigatus*, Colombia, 2015. *Emerging*
469 *infectious diseases* **22**, 156-157 (2016).

- 470 77. C. Sharma, F. Hagen, R. Moroti, J. F. Meis, A. Chowdhary, Triazole-resistant
471 *Aspergillus fumigatus* harbouring G54 mutation: Is it de novo or environmentally
472 acquired? *Journal of global antimicrobial resistance* **3**, 69-74 (2015).
- 473 78. I. Perveen, S. Sehar, I. Naz, S. Ahmed, in *Proceedings of the 7th Advances Against*
474 *Aspergillosis conference*. (Manchester, UK, 2016), pp. 3–5 March 2016.
- 475 79. A. Riat, J. Plojoux, K. Gindro, J. Schrenzel, D. Sanglard, Azole resistance of
476 environmental and clinical *Aspergillus fumigatus* isolates from Switzerland.
477 *Antimicrob Agents Chemother* **62**, (2018).
- 478 80. S. S. Goncalves, Global aspects of triazole resistance in *Aspergillus fumigatus* with
479 focus on Latin American Countries. *Journal of fungi (Basel, Switzerland)* **3**, (2017).
- 480 81. J. F. Ryley, R. G. Wilson, K. J. Barrett-Bee, Azole resistance in *Candida albicans*.
481 *Sabouraudia* **22**, 53-63 (1984).
- 482 82. A. Tavitian *et al.*, Ketoconazole-resistant *Candida* esophagitis in patients with
483 acquired immunodeficiency syndrome. *Gastroenterology* **90**, 443-445 (1986).
- 484 83. H. Dermoumi, In vitro susceptibility of yeast isolates from the blood to fluconazole
485 and amphotericin B. *Chemotherapy* **38**, 112-117 (1992).
- 486 84. N. Troillet, C. Durussel, J. Bille, M. P. Glauser, J. P. Chave, Correlation between in
487 vitro susceptibility of *Candida albicans* and fluconazole-resistant oropharyngeal
488 candidiasis in HIV-infected patients. *European journal of clinical microbiology &*
489 *infectious diseases : official publication of the European Society of Clinical*
490 *Microbiology* **12**, 911-915 (1993).
- 491 85. A. Budak, Epidemiology of *Candida* infection. II. Application of biochemical methods
492 for typing of *Candida albicans* strains. *Archivum immunologiae et therapiae*
493 *experimentalis* **38**, 369-377 (1990).
- 494 86. J. Dupouy-Camet *et al.*, Resistance to fluconazole in hospitalized patients.
495 Concordance between *Candida albicans* resistance *in vitro* and therapeutic failure.
496 *Presse medicale (Paris, France : 1983)* **20**, 1341 (1991).
- 497 87. F. Barchiesi *et al.*, Fluconazole and ketoconazole in the treatment of oral and
498 esophageal candidiasis in AIDS patients. *Journal of chemotherapy (Florence, Italy)* **4**,
499 381-386 (1992).

- 500 88. F. Dronda, J. L. Rodriguez-Tudela, P. Mera, J. Martinez-Suarez, Esophagitis caused by
501 fluconazole-resistant *Candida albicans*: therapeutic failure and *in vitro* correlation.
502 *Medicina clinica* **99**, 199 (1992).
- 503 89. T. G. Abrahamsen, E. Widing, A. Glomstein, P. Gaustad, Disseminated fungal disease
504 resistant to fluconazole treatment in a child with leukemia. *Scandinavian journal of*
505 *infectious diseases* **24**, 391-393 (1992).
- 506 90. C. H. Hauman, I. O. Thompson, F. Theunissen, P. Wolfaardt, Oral carriage of *Candida*
507 in healthy and HIV-seropositive persons. *Oral surgery, oral medicine, and oral*
508 *pathology* **76**, 570-572 (1993).
- 509 91. F. Allerberger *et al.*, *In vitro* susceptibility of *Candida albicans*, Austria 1992. *Mycoses*
510 **36**, 411-416 (1993).
- 511 92. P. J. Gallagher *et al.*, Reduced azole susceptibility of oral isolates of *Candida albicans*
512 from HIV-positive patients and a derivative exhibiting colony morphology variation. *J*
513 *Gen Microbiol* **138**, 1901-1911 (1992).
- 514 93. Y. C. Chen, S. C. Chang, W. C. Hsieh, K. T. Luh, *In vitro* antifungal susceptibilities of
515 *Candida* species isolated from the blood. *Int J Antimicrob Agents* **7**, 217-222 (1996).
- 516 94. E. Chryssanthou, J. Torssander, B. Petrini, Oral *Candida albicans* isolates with
517 reduced susceptibility to fluconazole in Swedish HIV-infected patients. *Scandinavian*
518 *journal of infectious diseases* **27**, 391-395 (1995).
- 519 95. R. Rautemaa *et al.*, Decreased susceptibility of *Candida albicans* to azole antifungals:
520 a complication of long-term treatment in autoimmune polyendocrinopathy-
521 candidiasis-ectodermal dystrophy (APECED) patients. *The Journal of antimicrobial*
522 *chemotherapy* **60**, 889-892 (2007).
- 523 96. A. Velegaki, D. Papalambrou, S. Soremi, N. J. Legakis, Variable antifungal
524 susceptibility of wild-type *Candida albicans* phenotypes from neutropenic hosts.
525 *European journal of clinical microbiology & infectious diseases : official publication of*
526 *the European Society of Clinical Microbiology* **15**, 854-860 (1996).
- 527 97. G. F. Araj, N. K. Daher, Z. A. Tabbarah, Antifungal susceptibility of *Candida* isolates at
528 the American University of Beirut Medical Center. *Int J Antimicrob Agents* **10**, 291-
529 296 (1998).

- 530 98. S. Fujita, Studies on microtiter broth dilution method for antifungal susceptibility
531 testing of yeast isolates from blood and cerebrospinal fluid. *Rinsho byori. The*
532 *Japanese journal of clinical pathology* **44**, 373-378 (1996).
- 533 99. J. Meis, M. Petrou, J. Bille, D. Ellis, D. Gibbs, A global evaluation of the susceptibility
534 of *Candida* species to fluconazole by disk diffusion. Global Antifungal Surveillance
535 Group. *Diagn Microbiol Infect Dis* **36**, 215-223 (2000).
- 536 100. K. C. Hazen *et al.*, Comparison of the susceptibilities of *Candida* spp. to fluconazole
537 and voriconazole in a 4-year global evaluation using disk diffusion. *J Clin Microbiol*
538 **41**, 5623-5632 (2003).
- 539 101. K. N. Prasad *et al.*, Role of yeasts as nosocomial pathogens & their susceptibility to
540 fluconazole & amphotericin B. *The Indian journal of medical research* **110**, 11-17
541 (1999).
- 542 102. M. A. Pfaller *et al.*, International surveillance of blood stream infections due to
543 *Candida* species in the European SENTRY Program: species distribution and
544 antifungal susceptibility including the investigational triazole and echinocandin
545 agents. SENTRY Participant Group (Europe). *Diagn Microbiol Infect Dis* **35**, 19-25
546 (1999).
- 547 103. A. L. Colombo, D. Da Matta, L. P. De Almeida, R. Rosas, Fluconazole susceptibility of
548 Brazilian *Candida* isolates assessed by a disk diffusion method. *The Brazilian journal*
549 *of infectious diseases : an official publication of the Brazilian Society of Infectious*
550 *Diseases* **6**, 118-123 (2002).
- 551 104. Z. Samra, M. Yardeni, N. Peled, J. Bishara, Species distribution and antifungal
552 susceptibility of *Candida* bloodstream isolates in a tertiary medical center in Israel.
553 *European journal of clinical microbiology & infectious diseases : official publication of*
554 *the European Society of Clinical Microbiology* **24**, 592-595 (2005).
- 555 105. G. S. Bulmer, M. L. Marquez, L. Co-Barcelona, R. A. Fromtling, Yeasts and fluconazole
556 susceptibility in the Philippines. *Mycopathologia* **146**, 117-120 (1999).
- 557 106. L. R. Asmundsdottir, H. Erlendsdottir, M. Gottfredsson, Increasing incidence of
558 candidemia: results from a 20-year nationwide study in Iceland. *J Clin Microbiol* **40**,
559 3489-3492 (2002).

- 560 107. M. S. Ellabib, I. A. ElJariny, *In vitro* activity of 6 antifungal agents on *Candida* species
561 isolated as causative agents from vaginal and other clinical specimens. *Saudi medical*
562 *journal* **22**, 860-863 (2001).
- 563 108. M. C. Arendrup *et al.*, Seminal surveillance of fungemia in Denmark: notably
564 high rates of fungaemia and numbers of isolates with reduced azole susceptibility. *J*
565 *Clin Microbiol* **43**, 4434-4440 (2005).
- 566 109. C. Tapia *et al.*, Antifungal susceptibility for *Candida albicans* isolated from AIDS
567 patients with oropharyngeal and esophageal candidiasis: experience with Etest.
568 *Revista medica de Chile* **131**, 515-519 (2003).
- 569 110. C. A. Enwuru *et al.*, Fluconazole resistant opportunistic oro-pharyngeal *Candida* and
570 non-*Candida* yeast-like isolates from HIV infected patients attending ARV clinics in
571 Lagos, Nigeria. *African health sciences* **8**, 142-148 (2008).
- 572 111. J. I. Yoo *et al.*, National surveillance of antifungal susceptibility of *Candida* species in
573 South Korean hospitals. *Med Mycol* **47**, 554-558 (2009).
- 574 112. L. O. Sanchez-Vargas *et al.*, Oral *Candida* isolates colonizing or infecting human
575 immunodeficiency virus-infected and healthy persons in Mexico. *J Clin Microbiol* **43**,
576 4159-4162 (2005).
- 577 113. E. M. Mokaddas, N. A. Al-Sweih, Z. U. Khan, Species distribution and antifungal
578 susceptibility of *Candida* bloodstream isolates in Kuwait: a 10-year study. *Journal of*
579 *medical microbiology* **56**, 255-259 (2007).
- 580 114. A. Sellami *et al.*, Antifungal susceptibility of bloodstream *Candida* isolates in Sfax
581 hospital: Tunisia. *Mycopathologia* **171**, 417-422 (2011).
- 582 115. E. Skrodeniene, A. Dambrauskiene, A. Vitkauskiene, Susceptibility of yeasts to
583 antifungal agents in Kaunas University of Medicine Hospital. *Medicina (Kaunas,*
584 *Lithuania)* **42**, 294-299 (2006).
- 585 116. C. M. Fernandez Andreu *et al.*, *In vitro* susceptibility of *Candida* strains to fluconazole
586 and amphotericin B. *Revista cubana de medicina tropical* **59**, 113-118 (2007).
- 587 117. A. Mulu *et al.*, Frequent detection of 'azole' resistant *Candida* species among late
588 presenting AIDS patients in northwest Ethiopia. *BMC infectious diseases* **13**, 82
589 (2013).
- 590 118. M. Mares, M. Mares, M. Rusu, Antifungal susceptibility of 95 yeast strains isolated
591 from oral mycoses in HIV-negative and HIV-positive patients. *Bacteriologia,*

- 592 *virusologia, parazitologia, epidemiologia (Bucharest, Romania : 1990)* **53**, 41-42
593 (2008).
- 594 119. G. Barada, R. Basma, R. A. Khalaf, Microsatellite DNA identification and genotyping
595 of *Candida albicans* from Lebanese clinical isolates. *Mycopathologia* **165**, 115-125
596 (2008).
- 597 120. P. Badiie, A. Alborzi, M. A. Davarpanah, E. Shakiba, Distributions and antifungal
598 susceptibility of *Candida* species from mucosal sites in HIV positive patients. *Archives*
599 *of Iranian medicine* **13**, 282-287 (2010).
- 600 121. J. Q. Farooqi *et al.*, Invasive candidiasis in Pakistan: clinical characteristics, species
601 distribution and antifungal susceptibility. *Journal of medical microbiology* **62**, 259-
602 268 (2013).
- 603 122. F. Mutua, G. Revathi, J. M. Machoki, Species distribution and antifungal sensitivity
604 patterns of vaginal yeasts. *East African medical journal* **87**, 156-162 (2010).
- 605 123. P. M. Dos Santos Abrantes, C. P. McArthur, C. W. Africa, Multi-drug resistant oral
606 *Candida* species isolated from HIV-positive patients in South Africa and Cameroon.
607 *Diagn Microbiol Infect Dis* **79**, 222-227 (2014).
- 608 124. M. Hegazi, A. Abdelkader, M. Zaki, B. El-Deek, Characteristics and risk factors of
609 candidemia in paediatric intensive care unit of a tertiary care children's hospital in
610 Egypt. *Journal of infection in developing countries* **8**, 624-634 (2014).
- 611 125. K. J. Mukasa *et al.*, Antifungal susceptibility patterns of vulvovaginal *Candida* species
612 among women attending antenatal clinic at Mbarara Regional Referral Hospital,
613 South Western Uganda. *British microbiology research journal* **5**, 322-331 (2015).
- 614 126. V. Arsic Arsenijevic *et al.*, *Candida* bloodstream infections in Serbia: First multicentre
615 report of a national prospective observational survey in intensive care units.
616 *Mycoses* **61**, 70-78 (2018).
- 617 127. A. J. Morris, K. Rogers, W. P. McKinney, S. A. Roberts, J. T. Freeman, Antifungal
618 susceptibility results of New Zealand yeast isolates, 2001-2015: Impact of recent CLSI
619 breakpoints and epidemiological cutoff values for *Candida* and other yeast species.
620 *Journal of global antimicrobial resistance*, (2018).
- 621 128. S. R. Lockhart *et al.*, Simultaneous emergence of multidrug-resistant *Candida auris*
622 on 3 continents confirmed by whole-genome sequencing and epidemiological

623 analyses. *Clinical infectious diseases : an official publication of the Infectious Diseases*
624 *Society of America* **64**, 134-140 (2017).

625 129. A. Chowdhary, C. Sharma, J. F. Meis, *Candida auris*: A rapidly emerging cause of
626 hospital-acquired multidrug-resistant fungal infections globally. *PLoS Pathog* **13**,
627 e1006290 (2017).

628 130. S. Vallabhaneni *et al.*, Investigation of the first seven reported cases of *Candida*
629 *auris*, a globally emerging invasive, multidrug-resistant fungus - United States, May
630 2013-August 2016. *MMWR. Morbidity and mortality weekly report* **65**, 1234-1237
631 (2016).

632 131. C. M. Parra-Giraldo *et al.*, First report of sporadic cases of *Candida auris* in Colombia.
633 *International journal of infectious diseases : IJID : official publication of the*
634 *International Society for Infectious Diseases* **69**, 63-67 (2018).

635 132. M. Emara *et al.*, *Candida auris* candidemia in Kuwait, 2014. *Emerging infectious*
636 *diseases* **21**, 1091-1092 (2015).

637 133. S. Schelenz *et al.*, First hospital outbreak of the globally emerging *Candida auris* in a
638 European hospital. *Antimicrobial resistance and infection control* **5**, 35 (2016).

639 134. A. B. Arauz *et al.*, Isolation of *Candida auris* from 9 patients in Central America:
640 Importance of accurate diagnosis and susceptibility testing. *Mycoses* **61**, 44-47
641 (2018).

642 135. D. W. Warnock *et al.*, Fluconazole resistance in *Candida glabrata*. *Lancet* **2**, 1310
643 (1988).

644 136. M. C. Arilla *et al.*, Vulvovaginal candidiasis refractory to treatment with fluconazole.
645 *European journal of obstetrics, gynecology, and reproductive biology* **44**, 77-80
646 (1992).

647 137. F. Barchiesi, A. L. Colombo, D. A. McGough, M. G. Rinaldi, Comparative study of
648 broth macrodilution and microdilution techniques for in vitro antifungal
649 susceptibility testing of yeasts by using the National Committee for Clinical
650 Laboratory Standards' proposed standard. *J Clin Microbiol* **32**, 2494-2500 (1994).

651 138. P. Chavanet *et al.*, Cross-sectional study of the susceptibility of *Candida* isolates to
652 antifungal drugs and *in vitro-in vivo* correlation in HIV-infected patients. *AIDS*
653 *(London, England)* **8**, 945-950 (1994).

- 654 139. A. Spinillo *et al.*, Frequency and significance of drug resistance in vulvovaginal
655 candidiasis. *Gynecologic and obstetric investigation* **38**, 130-133 (1994).
- 656 140. J. Berenguer, V. Fernandez-Baca, R. Sanchez, E. Bouza, *In vitro* activity of
657 amphotericin B, flucytosine and fluconazole against yeasts causing bloodstream
658 infections. *European journal of clinical microbiology & infectious diseases : official
659 publication of the European Society of Clinical Microbiology* **14**, 362-365 (1995).
- 660 141. P. Piemonte *et al.*, Emergency of fluconazole-resistant infections by *Candida krusei*
661 and *Candida glabrata* in neutropenic patients. *Revista medica de Chile* **124**, 1149
662 (1996).
- 663 142. K. P. Ng, T. L. Saw, S. L. Na, T. S. Soo-Hoo, Systemic *Candida* infection in University
664 hospital 1997-1999: the distribution of *Candida* biotypes and antifungal susceptibility
665 patterns. *Mycopathologia* **149**, 141-146 (2001).
- 666 143. M. A. Ribeiro, R. Dietze, C. R. Paula, D. A. Da Matta, A. L. Colombo, Susceptibility
667 profile of vaginal yeast isolates from Brazil. *Mycopathologia* **151**, 5-10 (2001).
- 668 144. P. R. Hsueh, L. J. Teng, P. C. Yang, S. W. Ho, K. T. Luh, Emergence of nosocomial
669 candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased
670 susceptibility of *Candida* species to fluconazole. *Microbial drug resistance
671 (Larchmont, N.Y.)* **8**, 311-319 (2002).
- 672 145. Y. Zer, I. Balci, G. Meric, Identification and antifungal susceptibility of *Candida*
673 isolated from intensive care unit patients. *The new microbiologica* **25**, 489-494
674 (2002).
- 675 146. M. T. Mujica, J. L. Finquelievich, V. Jewtuchowicz, C. A. Iovannitti, Prevalence of
676 *Candida albicans* and *Candida non-albicans* in clinical samples during 1999-2001.
677 *Revista Argentina de microbiologia* **36**, 107-112 (2004).
- 678 147. L. L. Oon, M. G. Yeo, Fluconazole susceptibility of *Candida* species in Singapore by
679 disc diffusion test. *Annals of the Academy of Medicine, Singapore* **31**, 497-501
680 (2002).
- 681 148. D. Swinne *et al.*, A one-year survey of candidemia in Belgium in 2002. *Epidemiology
682 and infection* **132**, 1175-1180 (2004).
- 683 149. E. Chryssanthou, H. Cherif, B. Petrini, M. Kalin, M. Bjorkholm, Surveillance of triazole
684 susceptibility of colonizing yeasts in patients with haematological malignancies.
685 *Scandinavian journal of infectious diseases* **36**, 855-859 (2004).

- 686 150. M. Sojakova, D. Liptajova, M. Borovsky, J. Subik, Fluconazole and itraconazole
687 susceptibility of vaginal yeast isolates from Slovakia. *Mycopathologia* **157**, 163-169
688 (2004).
- 689 151. G. St-Germain *et al.*, Epidemiology and antifungal susceptibility of bloodstream
690 *Candida* isolates in Quebec: Report on 453 cases between 2003 and 2005. *The*
691 *Canadian journal of infectious diseases & medical microbiology = Journal canadien*
692 *des maladies infectieuses et de la microbiologie medicale* **19**, 55-62 (2008).
- 693 152. J. H. Meurman *et al.*, Prevalence and antifungal drug sensitivity of non-albicans
694 *Candida* in oral rinse samples of self-caring elderly. *Gerodontology* **28**, 246-252
695 (2011).
- 696 153. A. Varma, K. J. Kwon-Chung, Heteroresistance of *Cryptococcus gattii* to fluconazole.
697 *Antimicrob Agents Chemother* **54**, 2303-2311 (2010).
- 698 154. J. W. Cheong, J. McCormack, Fluconazole resistance in cryptococcal disease:
699 emerging or intrinsic? *Med Mycol* **51**, 261-269 (2013).
- 700 155. W. Peetermans, H. Bobbaers, J. Verhaegen, J. Vandepitte, Fluconazole-resistant
701 *Cryptococcus neoformans* var *gattii* in an AIDS patient. *Acta clinica Belgica* **48**, 405-
702 409 (1993).
- 703 156. H. K. Tseng *et al.*, Microbiological, epidemiological, and clinical characteristics and
704 outcomes of patients with cryptococcosis in Taiwan, 1997-2010. *PLoS One* **8**, e61921
705 (2013).
- 706 157. R. S. Gutch *et al.*, Antifungal susceptibility of clinical and environmental *Cryptococcus*
707 *neoformans* and *Cryptococcus gattii* isolates in Jabalpur, a city of Madhya Pradesh in
708 Central India. *Brazilian journal of microbiology : [publication of the Brazilian Society*
709 *for Microbiology]* **46**, 1125-1133 (2015).
- 710 158. S. T. Tay, T. Tanty Haryanty, K. P. Ng, M. Y. Rohani, H. Hamimah, *In vitro*
711 susceptibilities of Malaysian clinical isolates of *Cryptococcus neoformans* var. *grubii*
712 and *Cryptococcus gattii* to five antifungal drugs. *Mycoses* **49**, 324-330 (2006).
- 713 159. O. C. Favalessa *et al.*, First description of phenotypic profile and *in vitro* drug
714 susceptibility of *Cryptococcus* spp yeast isolated from HIV-positive and HIV-negative
715 patients in State of Mato Grosso. *Revista da Sociedade Brasileira de Medicina*
716 *Tropical* **42**, 661-665 (2009).

- 717 160. F. Hagen, R. Hare Jensen, J. F. Meis, M. C. Arendrup, Molecular epidemiology and *in vitro* antifungal susceptibility testing of 108 clinical *Cryptococcus neoformans sensu lato* and *Cryptococcus gattii sensu lato* isolates from Denmark. *Mycoses* **59**, 576-584
718
719 (2016).
720
- 721 161. W. Dongmo *et al.*, *In Vitro* antifungal susceptibility of environmental isolates of
722 *Cryptococcus* spp. from the West Region of Cameroon. *Ethiopian journal of health*
723 *sciences* **26**, 555-560 (2016).
- 724 162. K. G. Davey, E. M. Johnson, A. D. Holmes, A. Szekely, D. W. Warnock, *In-vitro*
725 susceptibility of *Cryptococcus neoformans* isolates to fluconazole and itraconazole.
726 *The Journal of antimicrobial chemotherapy* **42**, 217-220 (1998).
- 727 163. M. A. Pfaller *et al.*, *In vitro* activities of voriconazole, fluconazole, and itraconazole
728 against 566 clinical isolates of *Cryptococcus neoformans* from the United States and
729 Africa. *Antimicrob Agents Chemother* **43**, 169-171 (1999).
- 730 164. A. Armengou, C. Porcar, J. Mascaró, F. Garcia-Bragado, Possible development of
731 resistance to fluconazole during suppressive therapy for AIDS-associated
732 cryptococcal meningitis. *Clinical infectious diseases : an official publication of the*
733 *Infectious Diseases Society of America* **23**, 1337-1338 (1996).
- 734 165. J. Chandenier *et al.*, *In vitro* activity of amphotericin B, fluconazole and voriconazole
735 against 162 *Cryptococcus neoformans* isolates from Africa and Cambodia. *European*
736 *journal of clinical microbiology & infectious diseases : official publication of the*
737 *European Society of Clinical Microbiology* **23**, 506-508 (2004).
- 738 166. H. Yamaguchi *et al.*, The *in vitro* antifungal activities of fluconazole against
739 pathogenic yeasts recently isolated from clinical specimens. *The Japanese journal of*
740 *antibiotics* **50**, 799-805 (1997).
- 741 167. S. H. Alves, J. O. Lopes, J. M. Costa, C. Klock, Development of secondary resistance to
742 fluconazole in *Cryptococcus neoformans* isolated from a patient with AIDS. *Revista*
743 *do Instituto de Medicina Tropical de Sao Paulo* **39**, 359-361 (1997).
- 744 168. P. Mondon *et al.*, Heteroresistance to fluconazole and voriconazole in *Cryptococcus*
745 *neoformans*. *Antimicrob Agents Chemother* **43**, 1856-1861 (1999).
- 746 169. M. K. Lee, D. Yong, M. Kim, M. N. Kim, K. Lee, Species distribution and antifungal
747 susceptibilities of yeast clinical isolates from three hospitals in Korea, 2001 to 2007.
748 *The Korean journal of laboratory medicine* **30**, 364-372 (2010).

- 749 170. Y. C. Chen *et al.*, Increasing trend of fluconazole-non-susceptible *Cryptococcus*
750 *neoformans* in patients with invasive cryptococcosis: a 12-year longitudinal study.
751 *BMC infectious diseases* **15**, 277 (2015).
- 752 171. A. Trpkovic, M. Pekmezovic, A. Barac, L. Crncevic Radovic, V. Arsic Arsenijevic, *In*
753 *vitro* antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and
754 itraconazole against *Cryptococcus neoformans* isolated from cerebrospinal fluid and
755 blood from patients in Serbia. *Journal de mycologie medicale* **22**, 243-248 (2012).
- 756 172. C. C. Bii *et al.*, Antifungal drug susceptibility of *Cryptococcus neoformans* from clinical
757 sources in Nairobi, Kenya. *Mycoses* **50**, 25-30 (2007).
- 758 173. O. Dorneanu *et al.*, Cryptococcus meningitis, five years of experience and literature
759 review. *Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi* **112**,
760 100-103 (2008).
- 761 174. E. Dannaoui *et al.*, Comparison of antifungal MICs for yeasts obtained using the
762 EUCAST method in a reference laboratory and the Etest in nine different hospital
763 laboratories. *Clinical microbiology and infection : the official publication of the*
764 *European Society of Clinical Microbiology and Infectious Diseases* **16**, 863-869 (2010).
- 765 175. T. Bicanic, T. Harrison, A. Niepieklo, N. Dyakopu, G. Meintjes, Symptomatic relapse of
766 HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the
767 role of fluconazole resistance and immune reconstitution. *Clinical infectious diseases*
768 *: an official publication of the Infectious Diseases Society of America* **43**, 1069-1073
769 (2006).
- 770 176. C. S. Matos, A. de Souza Andrade, N. S. Oliveira, T. F. Barros, Microbiological
771 characteristics of clinical isolates of *Cryptococcus* spp. in Bahia, Brazil: molecular
772 types and antifungal susceptibilities. *European journal of clinical microbiology &*
773 *infectious diseases : official publication of the European Society of Clinical*
774 *Microbiology* **31**, 1647-1652 (2012).
- 775 177. A. B. Khyriem, S. Sujatha, S. C. Parija, Antifungal susceptibility of *Cryptococcus*
776 *neoformans* to amphotericin B and fluconazole. *Indian journal of pathology &*
777 *microbiology* **49**, 307-308 (2006).
- 778 178. P. Escandon *et al.*, Cryptococcosis in Colombia: results of the national surveillance
779 program for the years 2006-2010. *Biomedica : revista del Instituto Nacional de Salud*
780 **32**, 386-398 (2012).

- 781 179. H. Wang *et al.*, *In vitro* susceptibilities of yeast species to fluconazole and
782 voriconazole as determined by the 2010 National China Hospital Invasive Fungal
783 Surveillance Net (CHIF-NET) study. *J Clin Microbiol* **50**, 3952-3959 (2012).
- 784 180. M. Seilmaier, A. Hecht, W. Guggemos, K. Rudisser, Cryptococcal meningoencephalitis
785 related to HIV infection with resistance to fluconazole, relapse, and IRIS.
786 *Medizinische Klinik (Munich, Germany : 1983)* **104**, 58-62 (2009).
- 787 181. T. Kammalac Ngouana *et al.*, Cryptococcal meningitis in Yaounde (Cameroon) HIV
788 infected patients: Diagnosis, frequency and *Cryptococcus neoformans* isolates
789 susceptibility study to fluconazole. *Journal de mycologie medicale* **25**, 11-16 (2015).
- 790 182. H. S. Chong, R. Dagg, R. Malik, S. Chen, D. Carter, *In vitro* susceptibility of the yeast
791 pathogen *Cryptococcus* to fluconazole and other azoles varies with molecular
792 genotype. *J Clin Microbiol* **48**, 4115-4120 (2010).
- 793 183. W. Pan *et al.*, Resistance of Asian *Cryptococcus neoformans* serotype A is confined to
794 few microsatellite genotypes. *PLoS One* **7**, e32868 (2012).
- 795 184. M. E. Bosco-Borgeat *et al.*, Amino acid substitution in *Cryptococcus neoformans*
796 lanosterol 14- α -demethylase involved in fluconazole resistance in clinical
797 isolates. *Revista Argentina de microbiologia* **48**, 137-142 (2016).
- 798 185. T. J. Proffer *et al.*, Occurrence, distribution, and polymerase chain reaction-based
799 detection of resistance to sterol demethylation inhibitor fungicides in populations of
800 *Blumeriella jaapii* in Michigan. *Phytopathology* **96**, 709-717 (2006).
- 801 186. Z. G. Ma, D. P. Morgan, D. Felts, T. J. Michailides, Sensitivity of *Botryosphaeria*
802 *dothidea* from California pistachio to tebuconazole. *Crop Protection* **21**, 829-835
803 (2002).
- 804 187. A. V. D. Pereira, R. B. Martins, S. J. Michereff, M. B. da Silva, M. P. S. Camara,
805 Sensitivity of *Lasiodiplodia theobromae* from Brazilian papaya orchards to MBC and
806 DMI fungicides. *European Journal of Plant Pathology* **132**, 489-498 (2012).
- 807 188. Y. Elad, Reduced sensitivity of *Botrytis cinerea* to 2 sterol biosynthesis-inhibiting
808 fungicides - fenetrazole and fenethanil. *Plant Pathology* **41**, 47-54 (1992).
- 809 189. C. Stehmann, M. A. DeWaard, Sensitivity of populations of *Botrytis cinerea* to
810 triazoles, benomyl and vinclozolin. *European Journal of Plant Pathology* **102**, 171-180
811 (1996).

- 812 190. P. Leroux, F. Chapeland, D. Desbrosses, M. Gredt, Patterns of cross-resistance to
813 fungicides in *Botryotinia fuckeliana* (*Botrytis cinerea*) isolates from French vineyards.
814 *Crop Protection* **18**, 687-697 (1999).
- 815 191. C. Q. Zhang, J. W. Zhu, F. L. Wei, S. Y. Liu, G. N. Zhu, Sensitivity of *Botrytis cinerea*
816 from greenhouse vegetables to DMIs and fenhexamid. *Phytoparasitica* **35**, 300-313
817 (2007).
- 818 192. V. Guarnaccia *et al.*, Emergence of Prochloraz-resistant populations of *Calonectria*
819 *pauciramosa* and *Calonectria polizzii* in ornamental nurseries of Southern Italy. *Plant*
820 *Disease* **98**, 344-350 (2013).
- 821 193. G. S. Karaoglanidis, P. M. Ioannidis, C. C. Thanassouloupoulos, Reduced sensitivity of
822 *Cercospora beticola* isolates to sterol-demethylation-inhibiting fungicides. *Plant*
823 *Pathology* **49**, 567-572 (2000).
- 824 194. G. A. Secor, V. V. Rivera, M. F. R. Khan, N. C. Gudmestad, Monitoring fungicide
825 sensitivity of *Cercospora beticola* of sugar beet for disease management decisions.
826 *Plant Disease* **94**, 1272-1282 (2010).
- 827 195. N. R. Trkulja *et al.*, Molecular and experimental evidence of multi-resistance of
828 *Cercospora beticola* field populations to MBC, DMI and QoI fungicides. *European*
829 *Journal of Plant Pathology* **149**, 895-910 (2017).
- 830 196. FRAC SBI Working Group. (Fungicide Resistance Action Committee, 2018).
- 831 197. K. L. Stevenson, P. F. Bertrand, T. B. Brenneman, Evidence for reduced sensitivity to
832 propiconazole in the pecan scab fungus in Georgia. *Phytopathology* **94**, S99-S99
833 (2004).
- 834 198. B. Cuendis, Universidad de Costa Rica, San José, Costa Rica (1988).
- 835 199. K.-C. Kuo, Sensitivity of mango anthracnose pathogen, *Colletotrichum*
836 *gloeosporioides*, to the fungicide prochloraz in Taiwan. *Proceedings of the National*
837 *Science Council Republic of China Part B Life Sciences* **25**, 174-179 (2001).
- 838 200. J. G. Gutierrez-Alonso *et al.*, Evaluation of resistance to Imazalil, Prochloraz and
839 Azoxystrobin of *Colletotrichum gloeosporioides* (Penz.) Penz. y Sacc. isolates, and
840 control of Mango (*Mangifera indica* L.) anthracnosis during Postharvest. *Revista*
841 *Mexicana de Fitopatología* **21**, 379-382 (2003).

- 842 201. D. Chen, H. Shi, H. Wu, Z. Xu, C. Zhang, Resistance of *Colletotrichum gloeosporioides*
843 causing grape ripe rot to thiophanate-methyl and tebuconazole in Zhejiang. *Journal*
844 *of Fruit Science* **30**, 665-668 (2013).
- 845 202. S. Chen, C. Luo, M. Hu, G. Schnabel, Characterization of resistance to DMI fungicides
846 in *Colletotrichum* spp. isolates from peach. *Phytopathology* **106**, 71-72 (2016).
- 847 203. C. Zhang *et al.*, Assessing the risk for resistance and elucidating the genetics of
848 *Colletotrichum truncatum* that is only sensitive to some DMI fungicides. *Frontiers in*
849 *Microbiology* **8**, 11 (2017).
- 850 204. J. T. Fletcher, M. S. Wolfe, in *British Crop Protection Conference- Pests and Diseases*.
851 (BCPC, Brighton, 1981), vol. 2, pp. 633-640.
- 852 205. M. S. Wolfe *et al.*, Barley mildew in Europe: population biology and host resistance.
853 *Euphytica* **63**, 125-139 (1992).
- 854 206. K. I. Almughrabi, A. B. Gray, Competition between triadimefon-sensitive and
855 triadimefon-resistant isolates of *Erysiphe graminis* f.sp. *tritici*. *Plant Disease* **79**, 709-
856 712 (1995).
- 857 207. FRAC SBI Working Group. (Fungicide Resistance Action Committee, 2016).
- 858 208. H. Buchenauer, K. H. Hellwald, Resistance of *Erysiphe graminis* on barley and wheat
859 to sterol C-14-demethylation inhibitors1. *EPPO Bulletin* **15**, 459-466 (1985).
- 860 209. M. A. De Waard, E. M. C. Kipp, N. M. Horn, J. G. M. Vannistelrooy, Variation in
861 sensitivity to fungicides which inhibit ergosterol biosynthesis in wheat powdery
862 mildew. *Netherlands Journal of Plant Pathology* **92**, 21-32 (1986).
- 863 210. Fungicide Resistance Action Committee. " List of Plant Pathogenic Organisms
864 Resistant to Disease Control Agents" <http://www.frac.info>; Retrieved 23/01/2018
865 (2017).
- 866 211. M. Svec, M. Miklovicova, M. Sykora, E. Krippel, Fungicide sensitivity of populations of
867 wheat powdery mildew (*Erysiphe graminis* f.sp. *tritici*) in Central Europe in 1993.
868 *Pesticide Science* **43**, 47-52 (1995).
- 869 212. Z. Ma *et al.*, Monitoring resistance of wheat powdery mildew to triadimefon. *Acta*
870 *Phytophylacica Sinica* **24**, 85-88 (1997).
- 871 213. R. A. Wyand, J. K. M. Brown, Sequence variation in the *CYP51* gene of *Blumeria*
872 *graminis* associated with resistance to sterol demethylase inhibiting fungicides.
873 *Fungal Genetics and Biology* **42**, 726-735 (2005).

- 874 214. FRAC SBI Working Group. (Fungicide Resistance Action Committee, 2017).
- 875 215. E. A. Meyers, R. Whetten, C. Cowger, Variation in sensitivity to DMI fungicides
876 tebuconazole and prothioconazole in *Blumeria graminis* f.sp *tritici*. *Phytopathology*
877 **107**, 32-32 (2017).
- 878 216. J. D. Weems, C. A. Bradley, Sensitivity of *Exserohilum turcicum* to demethylation
879 inhibitor fungicides. *Crop Protection* **99**, 85-92 (2017).
- 880 217. Y. Yin, X. Liu, B. Li, Z. Ma, characterization of sterol demethylation inhibitor-resistant
881 isolates of *Fusarium asiaticum* and *F. graminearum* collected from wheat in China.
882 *Phytopathology* **99**, 487-497 (2009).
- 883 218. F. Talas, B. A. McDonald, Significant variation in sensitivity to a DMI fungicide in field
884 populations of *Fusarium graminearum*. *Plant Pathology* **64**, 664-670 (2015).
- 885 219. P. Spolti, B. C. d. Jorge, E. M. Del Ponte, Sensitivity of *Fusarium graminearum* causing
886 head blight of wheat in Brazil to tebuconazole and metconazole fungicides. *Tropical*
887 *Plant Pathology* **37**, 419-423 (2012).
- 888 220. P. Spolti, E. M. Del Ponte, Y. H. Dong, J. A. Cummings, G. C. Bergstrom, Sensitivity in a
889 contemporary population of *Fusarium graminearum* from New York wheat and
890 competitiveness of a tebuconazole-resistant isolate. *Plant Disease* **98**, 607-613
891 (2014).
- 892 221. E. D. Nagygyorgy *et al.*, Toxicity of abiotic stressors to *Fusarium* species: differences
893 in hydrogen peroxide and fungicide tolerance. *Acta Microbiol. Immunol. Hung.* **61**,
894 189-208 (2014).
- 895 222. H. Yang, M. Ji, K. Yao, Z. Shu, Study on resistance of *Fusarium moniliforme* to
896 Prochloraz and its management. *Acta Agriculturae Jiangxi* **25**, 94-96, 105 (2013).
- 897 223. M. A. Yaghmour, R. M. Bostock, J. E. Adaskaveg, T. J. Michailides, Propiconazole
898 sensitivity in populations of *Geotrichum candidum*, the cause of sour rot of peach
899 and nectarine, in California. *Plant Disease* **96**, 752-758 (2012).
- 900 224. B. Sedlakova, A. Lebeda, Fungicide resistance in Czech populations of cucurbit
901 powdery mildews. *Phytoparasitica* **36**, 272-289 (2008).
- 902 225. A. P. Van de Wouw *et al.*, Identification of isolates of the plant pathogen
903 *Leptosphaeria maculans* with resistance to the triazole fungicide fluquinconazole
904 using a novel *in planta* assay. *Plos One* **12**, 19 (2017).

- 905 226. W. F. Liao *et al.*, Molecular mechanisms of drug sensitivity of rice blast fungi
906 *Magnaporthe grisea* to triazoles in China. *Fresenius Environ. Bull.* **27**, 320-326 (2018).
- 907 227. P. A. G. Elmer, M. Braithwaite, D. J. Saville, in *Fungicide Resistance*, S. Heaney *et al.*,
908 Eds. (1994), pp. 93-95.
- 909 228. E. I. Zehr, L. A. Luszcz, W. C. Olien, W. C. Newall, J. E. Toler, Reduced sensitivity in
910 *Monilinia fructicola* to propiconazole following prolonged exposure in peach
911 orchards. *Plant Disease* **83**, 913-916 (1999).
- 912 229. L. L. May-De Mio, Y. Luo, T. J. Michailides, Sensitivity of *Monilinia fructicola* from
913 Brazil to Tebuconazole, Azoxystrobin, and Thiophanate-Methyl and Implications for
914 Disease Management. *Plant Disease* **95**, 821-827 (2011).
- 915 230. B. Egueen, P. Melgarejo, A. De Cal, Sensitivity of *Monilinia fructicola* from Spanish
916 peach orchards to thiophanate-methyl, iprodione, and cyproconazole: fitness
917 analysis and competitiveness. *European Journal of Plant Pathology* **141**, 789-801
918 (2015).
- 919 231. R. A. Romero, T. B. Sutton, Sensitivity of *Mycosphaerella fijiensis*, causal agent of
920 Black Sigatoka of Banana, to Propiconazole. *Phytopathology* **87**, 96-100 (1997).
- 921 232. L. Perez, A. Hernandez, L. Hernandez, M. Perez, Effect of trifloxystrobin and
922 azoxystrobin on the control of black Sigatoka (*Mycosphaerella fijiensis* Morelet) on
923 banana and plantain. *Crop Protection* **21**, 17-23 (2002).
- 924 233. G. P. Canas-Gutierrez *et al.*, Analysis of the *CYP51* gene and encoded protein in
925 propiconazole-resistant isolates of *Mycosphaerella fijiensis*. *Pest Management*
926 *Science* **65**, 892-899 (2009).
- 927 234. FRAC Banana Working Group. (Fungicide Resistance Action Committee, 2015).
- 928 235. P. Chong *et al.*, in *Modern Fungicides and Antifungal Compounds VI. Proceedings of*
929 *the 16th International Reinhardtsbrunn Symposium April 25 -29, 2010, Friedrichroda,*
930 *Germany*, H. W. Dehne *et al.*, Eds. (DPG Spectrum Phytomedizin, Braunschweig,
931 Germany, 2010), pp. 217-222.
- 932 236. L. Martinez-Bolanos *et al.*, fungicide resistance on *Mycosphaerella fijiensis*
933 populations of southeastern Mexico. *Agrociencia* **46**, 707-717 (2012).
- 934 237. C. Guillermet, R. Le Guen, E. Foure, C. Cespedes, L. D. de Bellaire, Adaptation of the
935 forecasting system to control Black Leaf Streak Disease of banana in the specific
936 conditions of Dominican Republic. *Fruits* **69**, 261-278 (2014).

- 937 238. FRAC Banana Working Group. (Fungicide Resistance Action Committee, 2017).
- 938 239. J. Yamaguchi, M. Inada, M. Matsuzaki, Occurrence of DMI-fungicide-resistant isolates
939 of *Mycovellosiella natrassii* Deighton, causal fungus of leaf mold of eggplant.
940 *Japanese Journal of Phytopathology* **66**, 78-84 (2000).
- 941 240. J. W. Eckert, *Penicillium digitatum* biotypes with reduced sensitivity to imazalil.
942 *Phytopathology* **77**, 1728-1728 (1987).
- 943 241. V. G. Bus, A. J. Bongers, L. A. Risse, Occurrence of *Penicillium digitatum* and
944 *Penicillium italicum* resistant to benomyl thiabendazole and imazalil on citrus fruit
945 from different geographic origins. *Plant Disease* **75**, 1098-1100 (1991).
- 946 242. H. Hamamoto *et al.*, PCR-based detection of sterol demethylation inhibitor-resistant
947 strains of *Penicillium digitatum*. *Pest Management Science* **57**, 839-843 (2001).
- 948 243. M. Kellerman *et al.*, Classification of imazalil resistance in an international collection
949 of *Penicillium digitatum* isolates. *Canadian Journal of Plant Pathology* **39**, 133-137
950 (2017).
- 951 244. J. Wang *et al.*, Novel mutations in CYP51B from *Penicillium digitatum* Involved in
952 Prochloraz resistance. *J Microbiol* **52**, (2014).
- 953 245. D. A. S. Pereira, B. A. McDonald, P. C. Brunner, Mutations in the CYP51 gene reduce
954 DMI sensitivity in *Parastagonospora nodorum* populations in Europe and China. *Pest*
955 *Management Science* **73**, 1503-1510 (2017).
- 956 246. M. A. El-Goorani, H. M. El-Kasheir, M. T. Kabeel, A. A. Shoeib, Resistance to
957 benzimidazole fungicides of *Penicillium italicum* and *Penicillium digitatum* isolated
958 from packinghouses and orchards in egypt. *Plant Disease* **68**, 100-102 (1984).
- 959 247. G. J. Holmes, J. W. Eckert, Sensitivity of *Penicillium digitatum* and *P. italicum* to
960 postharvest citrus fungicides in California. *Phytopathology* **89**, 716-721 (1999).
- 961 248. L. J. Koga, I. O. N. Lopes, C. V. Godoy, *Sensitivity monitoring of Phakopsora pachyrhizi*
962 *populations to triazoles in Brazil*. H. W. Dehne *et al.*, Eds., Modern fungicides and
963 antifungal compounds VI. 16th International Reinhardsbrunn Symposium,
964 Friedrichroda, Germany, April 25-29, 2010 (Deutsche Phytomedizinische Gesellschaft
965 e.V. Selbstverlag, 2011), pp. 211-216.
- 966 249. A. Sombardier, M. C. Dufour, D. Blancard, M. F. Corio-Costet, Sensitivity of
967 *Podosphaera aphanis* isolates to DMI fungicides: distribution and reduced cross-
968 sensitivity. *Pest Management Science* **66**, 35-43 (2010).

- 969 250. P. Leroux, M. Gredt, Evolution of fungicide resistance in the cereal eyespot fungi
970 *Tapesia yallundae* and *Tapesia acuformis* in France. *Pesticide Science* **51**, 321-327
971 (1997).
- 972 251. S. Parnell, C. A. Gilligan, J. A. Lucas, C. H. Bock, F. van den Bosch, Changes in fungicide
973 sensitivity and relative species abundance in *Oculimacula yallundae* and *O. acuformis*
974 populations (eyespot disease of cereals) in Western Europe. *Plant Pathology* **57**, 509-
975 517 (2008).
- 976 252. B. Robbertse, G. Holz, P. W. Crous, Sensitivity of South African *Ramulispora*
977 *herpotrichoides* isolates to carbendazim and ergosterol biosynthesis inhibitors. *Plant*
978 *Pathology* **45**, 270-275 (1996).
- 979 253. P. S. Dyer, J. Hansen, A. Delaney, J. A. Lucas, Genetic control of resistance to the
980 sterol 14 α -demethylase inhibitor fungicide prochloraz in the cereal eyespot
981 pathogen *Tapesia yallundae*. *Applied and Environmental Microbiology* **66**, 4599-4604
982 (2000).
- 983 254. P. Matusinsky, I. Svacinova, A. Jonaviciene, L. Tvaruzek, Long-term dynamics of
984 causative agents of stem base diseases in winter wheat and reaction of Czech
985 *Oculimacula* spp. and *Microdochium* spp. populations to prochloraz. *European*
986 *Journal of Plant Pathology* **148**, 199-206 (2017).
- 987 255. E. K. Krebs, Problematical control of chrysanthemum white rust Bekämpfung des
988 Weissen Chrysanthemenrostes problematisch. *TASPO artenbaumagazin* **6**, 40-41
989 (1997).
- 990 256. R. T. A. Cook, First report in England of changes in the susceptibility of *Puccinia*
991 *horiana*, the cause of chrysanthemum white rust, to triazole and strobilurin
992 fungicides. *Plant Pathology* **50**, 792-792 (2001).
- 993 257. R. A. Bayles, Yellow rust of wheat - survey of sensitivity to DMI fungicides in 1997.
994 *HGCA Project Report*, 7 pp. (1998).
- 995 258. G. Stammler, J. Cordero, A. Koch, M. Semar, S. Schlehner, Role of the Y134F
996 mutation in *cyp51* and overexpression of *cyp51* in the sensitivity response of
997 *Puccinia triticina* to epoxiconazole. *Crop Protection* **28**, 891-897 (2009).
- 998 259. G. d. S. Arduim, E. M. Reis, A. L. Barcellos, C. Turra, *In vivo* sensitivity reduction of
999 *Puccinia triticina* races, causal agent of wheat leaf rust, to DMI and QoI fungicides.
1000 *Summa Phytopathologica* **38**, 306-311 (2012).

- 1001 260. H. E. Carter *et al.*, Alterations in the predicted regulatory and coding regions of the
1002 sterol 14 alpha-demethylase gene (*CYP51*) confer decreased azole sensitivity in the
1003 oilseed rape pathogen *Pyrenopeziza brassicae*. *Molecular Plant Pathology* **15**, 513-
1004 522 (2014).
- 1005 261. J. E. Sheridan, D. K. Nendick, in *Proceedings of the forty second New Zealand weed*
1006 *and pest control conference, Taranki Country Lodge, New Plymouth, August 8-10,*
1007 *1989.* (New Zealand Weed and Pest Control Society Inc., 1989), pp. 221-224.
- 1008 262. S. J. Kendall, in *Brighton Crop Protection Conference- Pests and Diseases.* (BCPC,
1009 Brighton, 1986), vol. 2, pp. 539-546.
- 1010 263. T. L. Peever, M. G. Milgroom, Lack of correlation between fitness and resistance to
1011 sterol biosynthesis-inhibiting fungicides in *Pyrenophora teres*. *Phytopathology* **84**,
1012 515-519 (1994).
- 1013 264. T. L. Peever, M. G. Milgroom, Inheritance of triadimenol resistance in *Pyrenophora-*
1014 *teres*. *Phytopathology* **82**, 821-828 (1992).
- 1015 265. G. F. Campbell, P. W. Crous, Fungicide sensitivity of South African net- and spot-type
1016 isolates of *Pyrenophora teres* to ergosterol biosynthesis inhibitors. *Australasian Plant*
1017 *Pathology* **31**, 151-155 (2002).
- 1018 266. A. Batur-Ciesniewska, A. Grabowski, D. Panka, Diversity in the polish isolates of
1019 *Drechslera teres* in spring barley as determined through morphological features,
1020 mating types, reaction to control agents and rapd markers. *J. Plant Pathol.* **94**, 339-
1021 351 (2012).
- 1022 267. W. J. Mair *et al.*, Demethylase inhibitor fungicide resistance in *Pyrenophora teres* f.
1023 sp. *teres* associated with target site modification and inducible overexpression of
1024 *Cyp51*. *Frontiers in Microbiology* **7**, (2016).
- 1025 268. S. Reimann, H. B. Deising, Inhibition of efflux transporter-mediated fungicide
1026 resistance in *Pyrenophora tritici-repentis* by a derivative of 4'-hydroxyflavone and
1027 enhancement of fungicide activity. *Applied and Environmental Microbiology* **71**,
1028 3269-3275 (2005).
- 1029 269. O. O. Ajayi-Oyetunde, C. J. Butts-Wilmsmeyer, C. A. Bradley, Sensitivity of
1030 *Rhizoctonia solani* to succinate dehydrogenase inhibitor and demethylation inhibitor
1031 fungicides. *Plant Disease* **101**, 487-495 (2016).

- 1032 270. M. Agrawal, S. Sunder, Variations in sensitivity of *Rhizoctonia solani* AG-1 IA isolates
1033 from rice to carbendazim and hexaconazole. *Journal of Mycology and Plant*
1034 *Pathology* **43**, 394 (2013).
- 1035 271. N. J. Hawkins *et al.*, Paralog Re-Emergence: A novel, historically contingent
1036 mechanism in the evolution of antimicrobial resistance. *Mol. Biol. Evol.* **31**, 1793-
1037 1802 (2014).
- 1038 272. B. Robbertse, M. van der Rijst, I. M. R. van Aarde, C. Lennox, P. Crous, DMI sensitivity
1039 and cross-resistance patterns of *Rhynchosporium secalis* isolates from South Africa.
1040 *Crop Protection* **20**, 97-102 (2001).
- 1041 273. P. C. Brunner, T. S. Stefansson, J. Fountaine, V. Richina, B. A. McDonald, A Global
1042 Analysis of CYP51 Diversity and Azole Sensitivity in *Rhynchosporium commune*.
1043 *Phytopathology* **106**, 355-361 (2016).
- 1044 274. J. M. Vargas, Jr., R. Golembiewski, A. R. Detweiler, Reduced sensitivity of *Sclerotinia*
1045 *homoeocarpa* to DMI fungicides. *Phytopathology* **82**, 1069 (1992).
- 1046 275. T. Hsiang, L. Yang, W. Barton, Baseline sensitivity and cross-resistance to
1047 demethylation-inhibiting fungicides in Ontario isolates of *Sclerotinia homoeocarpa*.
1048 *European Journal of Plant Pathology* **103**, 409-416 (1997).
- 1049 276. M. Mocioni, M. L. Gullino, A. Garibaldi, Sensitivity of *Sclerotinia homoeocarpa*
1050 isolates from turfgrass in Italy to demethylation-inhibiting (DMI) fungicides and
1051 iprodione. *Phytopathologia Mediterranea* **50**, 408-413 (2011).
- 1052 277. M. Chatzidimopoulos, A. C. Pappas, Epidemiology and control of *Septoria pyricola* in
1053 pear leaf and fruit. *J. Plant Pathol.* **98**, 447-452 (2016).
- 1054 278. J. M. Calabro, R. A. Spotts, G. L. Grove, Preliminary studies on sweet cherry powdery
1055 mildew resistance to DMI's in the Pacific Northwest. *Phytopathology* **96**, S18-S18
1056 (2006).
- 1057 279. H. Schepers, Persistence of resistance to fungicides in *Sphaerotheca fuliginea*.
1058 *Netherlands Journal of Plant Pathology* **90**, 165-171 (1984).
- 1059 280. F. Huggenberger, M. A. Collins, G. Skylakakis, Decreased sensitivity of *Sphaerotheca*
1060 *fuliginea* to fenarimol and other ergosterol-biosynthesis inhibitors. *Crop Protection*
1061 **3**, 137-149 (1984).
- 1062 281. M. T. McGrath, Fungicide resistance in cucurbit powdery mildew: Experiences and
1063 challenges. *Plant Disease* **85**, 236-245 (2001).

- 1064 282. N. Ohtsuka, K. Sou, T. Amano, Y. Nakazawa, Y. Yamada, Sensitivity of cucumber
1065 powdery mildew fungus (*Sphaerotheca fuliginea*) to several fungicides. *Journal of*
1066 *Pesticide Science* **16**, 271-273 (1991).
- 1067 283. R. G. Obrien, L. L. Vawdrey, R. J. Glass, Fungicide resistance in cucurbit powdery
1068 mildew (*Sphaerotheca fuliginea*) and its effect on field control. *Australian Journal of*
1069 *Experimental Agriculture* **28**, 417-423 (1988).
- 1070 284. Jinyoung, Hongsunseong, Imjaeuk, K. Y. Park, H. G. Kim, Screening of fungicide
1071 resistance of Cucumber Powdery Mildew pathogen, *Sphaerotheca fusca* in Gyeonggi
1072 Province. *Research in Plant Disease* **14**, 95-101 (2008).
- 1073 285. W. Goszczynski, J. Cimanowski, R. Bachnacki, First note on the occurrence of a strain
1074 of *Sphaerotheca mors-uvae* schw. berk. with decreased sensitivity to triadimefon.
1075 *Fruit Science Reports (Skierniewice)* **15**, 181-184 (1988).
- 1076 286. M. Reuveni, Improved control of powdery mildew (*Sphaerotheca pannosa*) of
1077 nectarines in Israel using strobilurin and polyoxin B fungicides; mixtures with sulfur;
1078 and early bloom applications. *Crop Protection* **20**, 663-668 (2001).
- 1079 287. H. X. Li, K. L. Stevenson, M. T. Brewer, Differences in sensitivity to a triazole fungicide
1080 among *Stagonosporopsis* species causing gummy stem blight of cucurbits. *Plant*
1081 *Disease* **100**, 2106-2112 (2016).
- 1082 288. D. Debieu, M. F. Coriocostet, H. Steva, C. Malosse, P. Leroux, Sterol composition of
1083 the vine powdery mildew fungus, *Uncinula necator* - comparison of triadimenol-
1084 sensitive and resistant strains. *Phytochemistry* **39**, 293-300 (1995).
- 1085 289. R. C. Pearson, D. G. Riegel, Evaluation of fungicides for control of powdery mildew of
1086 grapes, 1989. *Fungicide and Nematicide Tests* **45**, 74 (1990).
- 1087 290. C. Délye, F. Laigret, M. F. Corio-Costet, A mutation in the *14 alpha-demethylase* gene
1088 of *Uncinula necator* that correlates with resistance to a sterol biosynthesis inhibitor.
1089 *Applied and Environmental Microbiology* **63**, 2966-2970 (1997).
- 1090 291. S. Steinkellner, H. Redl, Sensitivity of *Uncinula necator* populations following DMI-
1091 fungicide usage in Austrian vineyards. *Bodenkultur* **52**, 293-299 (2001).
- 1092 292. F. Halleen, G. Holz, K. L. Pringle, Resistance in *Uncinula necator* to triazole fungicides
1093 in South African grapevines. *South African Journal of Enology and Viticulture* **21**, 71-
1094 80 (2000).

- 1095 293. S. Savocchia, B. E. Stummer, T. J. Wicks, R. van Heeswijck, E. S. Scott, Reduced
1096 sensitivity of *Uncinula necator* to sterol demethylation inhibiting fungicides in
1097 southern Australian vineyards. *Australasian Plant Pathology* **33**, 465-473 (2004).
- 1098 294. O. Frenkel, L. Cadle-Davidson, W. F. Wilcox, M. G. Milgroom, Mechanisms of
1099 resistance to an Azole fungicide in the grapevine powdery mildew fungus, *Erysiphe*
1100 *necator*. *Phytopathology* **105**, 370-377 (2015).
- 1101 295. P. D. Hildebrand, C. L. Lockhart, R. J. Newbery, R. G. Ross, Resistance of *Venturia*
1102 *inaequalis* to bitertanol and other demethylation-inhibiting fungicides. *Canadian*
1103 *Journal of Plant Pathology-Revue Canadienne De Phytopathologie* **10**, 311-316
1104 (1988).
- 1105 296. V. F. Stanis, A. L. Jones, Reduced sensitivity to sterol-inhibiting fungicides in field
1106 isolates of *Venturia inaequalis*. *Phytopathology* **75**, 1098-1101 (1985).
- 1107 297. T. S. Thind, M. Clerjeau, J. M. Olivier, First observations on resistance in *Venturia*
1108 *inaequalis* and *Guignardia bidwellii* to ergosterol-biosynthesis inhibitors in France.
1109 *1986 British Crop Protection Conference. Pests and Diseases. Vol. 2.*, 491-498 (1986).
- 1110 298. R. Fiaccadori, A. Gielink, J. Dekker, Sensitivity to inhibitors of sterol biosynthesis in
1111 isolates of *Venturia inaequalis* from Italian and Dutch orchards. *European Journal of*
1112 *Plant Pathology* **93**, 285-287 (1987).
- 1113 299. F. D. Smith, W. Koller, D. M. Parker, Baseline-sensitivity of three populations of
1114 *Venturia inaequalis* to flusilazole. *Phytopathology* **79**, 1171 (1989).
- 1115 300. H. G. Whelan, M. R. Butcher, R. E. Gaunt, Sensitivity of *Venturia inaequalis* (black
1116 spot) on apples to DMI fungicides in New Zealand. *Proceedings of the NZ Plant*
1117 *Protection Conference* **45**, 289-294 (1992).
- 1118 301. J. Kloutvorova, M. Lansky, J. Kupkova, *In vitro* estimation of some *Venturia inaequalis*
1119 Cke. Aderh. isolate responses to some fungicides. *Vedecke Prace Ovocnarske*, 29-36
1120 (2001).
- 1121 302. B. Meszka, A. Bielenin, Decrease of *Venturia inaequalis* (Cook) Aderh. sensitivity to
1122 dodine and sterol demethylation inhibitor fungicides. *Plant Protection Science* **38**,
1123 659-661 (2002).
- 1124 303. S. D. Hetherington, D. A. Gunning, Myclobutanil resistance in an isolate of *Venturia*
1125 *inaequalis* from New South Wales. *Australasian Plant Pathology* **32**, 121-122 (2003).

- 1126 304. X. M. Xu, L. Q. Gao, J. R. Yang, Are insensitivities of *Venturia inaequalis* to
1127 myclobutanil and fenbuconazole correlated? *Crop Protection* **29**, 183-189 (2010).
- 1128 305. J. L. Henriquez S, O. V. Sarmiento, P. Alarcon C, Sensitivity of *Venturia inaequalis*
1129 Chilean isolates to difenoconazole, fenarimol, mancozeb, and pyrimethanil. *Chilean*
1130 *Journal of Agricultural Research* **71**, 39-44 (2011).
- 1131 306. M. Stević, P. Vukša, I. Elezović, Resistance of *Venturia inaequalis* to demethylation
1132 inhibiting (DMI) fungicides. *Žemdirbystė=Agriculture*, 65-72 (2010).
- 1133 307. P. Mondino *et al.*, Sensitivity of *Venturia inaequalis* to Trifloxystrobin and
1134 Difenoconazole in Uruguay. *Journal of Phytopathology* **163**, 1-10 (2015).
- 1135 308. Y. Tomita, H. Ishii, Reduced sensitivity to fenarimol in Japanese field strains of
1136 *Venturia nashicola*. *Pesticide Science* **54**, 150-156 (1998).
- 1137 309. H. J. Hims, HGCA Project Report No. 91. Monitoring sensitivity to the DMI group of
1138 fungicides in populations of the leaf blotch pathogen (*Septoria tritici*) and the glume
1139 blotch pathogen (*Septoria nodorum*) of winter wheat. *HGCA Project Report No. 91.*
1140 *Monitoring sensitivity to the DMI group of fungicides in populations of the leaf blotch*
1141 *pathogen (Septoria tritici) and the glume blotch pathogen (Septoria nodorum) of*
1142 *winter wheat.*, 31 pp. (1994).
- 1143 310. P. C. Brunner, F. L. Stefanato, B. A. McDonald, Evolution of the CYP51 gene in
1144 *Mycosphaerella graminicola*: evidence for intragenic recombination and selective
1145 replacement. *Molecular Plant Pathology* **9**, 305-316 (2008).
- 1146 311. I. Stergiopoulos, J. G. M. van Nistelrooy, G. H. J. Kema, M. A. De Waard, Multiple
1147 mechanisms account for variation in base-line sensitivity to azole fungicides in field
1148 isolates of *Mycosphaerella graminicola*. *Pest Management Science* **59**, 1333-1343
1149 (2003).
- 1150 312. J. Zhan, F. L. Stefanato, B. A. McDonald, Selection for increased cyproconazole
1151 tolerance in *Mycosphaerella graminicola* through local adaptation and in response to
1152 host resistance. *Molecular Plant Pathology* **7**, 259-268 (2006).
- 1153 313. S. Kildea *et al.*, Sensitivity of *Mycosphaerella graminicola* populations in the Republic
1154 of Ireland to DMI and QoI fungicides. *Aspects of Applied Biology*, 59-64 (2006).
- 1155 314. G. Stammler *et al.*, Frequency of different CYP51-haplotypes of *Mycosphaerella*
1156 *graminicola* and their impact on epoxiconazole-sensitivity and -field efficacy. *Crop*
1157 *Protection* **27**, 1448-1456 (2008).

- 1158 315. S. Boukef, B. A. McDonald, A. Yahyaoui, S. Rezgui, P. C. Brunner, Frequency of
1159 mutations associated with fungicide resistance and population structure of
1160 *Mycosphaerella graminicola* in Tunisia. *European Journal of Plant Pathology* **132**,
1161 111-122 (2012).
- 1162 316. G. Stammler, M. Semar, Sensitivity of *Mycosphaerella graminicola* (anamorph:
1163 *Septoria tritici*) to DMI fungicides across Europe and impact on field performance.
1164 *EPPO Bulletin* **41**, 149-155 (2011).
- 1165 317. A. Mehl, U. Krieg, A. Suty-Heinze, *Mycosphaerella graminicola: relevance of in vitro*
1166 *sensitivity and cyp51 mutations for the field performance of DMI fungicides*. H. W.
1167 Dehne *et al.*, Eds., Modern fungicides and antifungal compounds VI. 16th
1168 International Reinhardsbrunn Symposium, Friedrichroda, Germany, April 25-29, 2010
1169 (2011), pp. 245-250.
- 1170 318. H. Sierotzki, R. Frey, C. Buitrago, J. Wullschleger, U. Gisi, *Sensitivity of European*
1171 *Mycosphaerella graminicola* populations to DMI fungicides. H. W. Dehne *et al.*, Eds.,
1172 Modern fungicides and antifungal compounds VI. 16th International Reinhardsbrunn
1173 Symposium, Friedrichroda, Germany, April 25-29, 2010 (2011), pp. 237-243.
- 1174 319. D. Strobel, R. Bryson, G. Stammler, M. Semar, *A European overview of the sensitivity*
1175 *of Mycosphaerella graminicola (Zymoseptoria tritici) to DMI fungicides in vitro and*
1176 *the relative impact on field performance*. H. W. Dehne *et al.*, Eds., Modern fungicides
1177 and antifungal compounds VII. Proceedings of the 17th International Reinhardsbrunn
1178 Symposium, April 21-25 2013, Friedrichroda, Germany (2014), pp. 257-262.
- 1179 320. L. K. Estep *et al.*, Emergence and early evolution of fungicide resistance in North
1180 American populations of *Zymoseptoria tritici*. *Plant Pathology* **64**, 961-971 (2015).
- 1181 321. A. Milgate, D. Adorada, B. Orchard, J. Pattemore, First report of resistance to DMI
1182 fungicides in Australian populations of the wheat pathogen *Zymoseptoria tritici*.
1183 *Plant Disease* **100**, 522-522 (2016).
- 1184 322. T. M. Stewart, A. J. Perry, M. J. Evans, Resistance of *Zymoseptoria tritici* to
1185 azoxystrobin and epoxiconazole in the lower North Island of New Zealand. *New*
1186 *Zealand Plant Protection* **67**, 304-313 (2014).
- 1187 323. T. M. Heick, A. F. Justesen, L. N. Jorgensen, Resistance of wheat pathogen
1188 *Zymoseptoria tritici* to DMI and QoI fungicides in the Nordic-Baltic region - a status.
1189 *European Journal of Plant Pathology* **149**, 669-682 (2017).

1190 324. L. N. Jorgensen *et al.*, Four azoles' profile in the control of Septoria, yellow rust and
1191 brown rust in wheat across Europe. *Crop Protection* **105**, 16-27 (2018).

1192

1193

1194 **Figure Legends**

1195

1196 **Figure 1.** Current antifungal drug classes used against plant and animal fungal infections,
1197 and their known resistance mechanisms. There are six main classes of fungicides. These are
1198 the morpholines, which inhibit two target sites within the ergosterol biosynthetic pathway,
1199 $\Delta 14$ -reductase and $\Delta 8$ - $\Delta 7$ -isomerase (this reduces the risk of target-site resistance, but their
1200 intrinsic antifungal activity spectrum is narrower); the azoles used also in animal infections),
1201 which target the ergosterol biosynthetic pathway; the MBCs (benzimidazoles), which
1202 interfere with the cytoskeleton by binding to β -tubulin, so preventing the assembly of
1203 microtubules; the Qols (strobilurins), and SDHIs (succinate dehydrogenase inhibitors), which
1204 both inhibit the electron transfer chain of mitochondrial respiration, with the SDHIs
1205 inhibiting complex II (succinate dehydrogenase) and the Qols inhibiting complex III
1206 (cytochrome b, Quinone outside binding pocket) and the anilinopyrimidines which may
1207 target mitochondrial signalling pathways.

1208

1209 **Figure 2.** Fungal species with reported antifungal resistance, by country. Increasing colour
1210 intensity (red scale) reflects growing number of reports. Plant map reports spatio-temporal
1211 records of resistance of crop pathogens to azoles. Human map reports spatio-temporal
1212 records of resistance of the pathogens *Aspergillus fumigatus*; *Candida albicans*, *C. auris* and
1213 *C. glabrata*; and *Cryptococcus gattii* and *C. neoformans* to azoles. Database derived from
1214 peer-reviewed publications as of March 2018, reporting cases of resistance occurring up to
1215 2017 available in Supplementary Information 1.

1216

1217 **Figure 3.** Evolutionary drivers of antifungal resistance: heritable variation, high reproductive
1218 output and differential survival.

1219

1220

1221 **Supplementary content**

1222 **Supplementary Table 1.** Published reports of azole fungicide resistance in plant and clinical
1223 pathogens, as illustrated in Figure 2. Plant records comprise spatio-temporal reports
1224 (country and year) of resistance to azoles in any plant pathogen species. Human records
1225 comprise spatio-temporal reports (country and year) of azole resistance in the pathogens
1226 *Candida albicans*, *C. glabrata*, *C. auris*, *Cryptococcus* spp., and *Aspergillus fumigatus*.
1227 Database derived from peer-reviewed publications as of March 2018, reporting cases of
1228 resistance occurring up to 2017.

1229

1230 **Supplementary content**

1231

1232 Supplementary Table 1. Published reports of azole fungicide resistance in plant and clinical
1233 pathogens, as illustrated in Figure 2. Plant records comprise spatio-temporal reports
1234 (country and year) of resistance to azoles in any plant pathogen species. Human records
1235 comprise spatio-temporal reports (country and year) of azole resistance in the pathogens
1236 *Aspergillus fumigatus*; *Candida albicans*, *C. auris* and *C. glabrata*; and *Cryptococcus gattii*
1237 and *C. neoformans*. Database derived from peer-reviewed publications as of March 2018,
1238 reporting cases of resistance occurring up to 2017.

1239

Pathogen	Country	Year ¹	Reference
Clinical pathogens			
<i>Aspergillus fumigatus</i>	United States	1989	(54)
	Sweden	1995	(55)
	Netherlands	1998	(56)
	Italy	1998	(57)
	Japan	1998	(58)
	United Kingdom	1999	(59)
	France	1999	(60)
	Turkey	2000	(61)
	Norway	2001	(62)

	Spain	2003	(63)
	Iran	2003	(64)
	Australia	2004	(65)
	India	2005	(66)
	Belgium	2006	(67)
	Poland	2006	(68)
	Denmark	2007	(69)
	China	2008	(70)
	Morocco	2010	(71)
	Germany	2011	(72)
	Taiwan	2011	(73)
	Kuwait	2013	(74)
	Tanzania	2013	(75)
	Colombia	2015	(76)
	Romania	2015	(77)
	Pakistan	2016	(78)
	Switzerland	2016	(79)
	Argentina	2017	(80)
<i>Candida albicans</i>	United Kingdom	1984	(81)
	USA	1984	(82)
	Germany	1985	(83)
	Switzerland	1990	(84)
	Poland	1990	(85)
	France	1991	(86)
	Italy	1992	(87)
	Spain	1992	(88)
	Scandinavia	1992	(89)
	South Africa	1992	(90)
	Austria	1992	(91)
	Ireland	1992	(92)
	China	1994	(93)
	Sweden	1995	(94)
	Finland	1995	(95)
	Greece	1996	(96)
	Lebanon	1996	(97)
	Japan	1996	(98)
	Argentina	1997	(99)
	Netherlands	1997	(99)
	Australia	1997	(99)
	Portugal	1997	(99)
	Thailand	1997	(99)
	Venezuela	1997	(99)
	Turkey	1997	(99)
	Czech Republic	1997	(100)
	Singapore	1997	(100)

	India	1997	(101)
	Canada	1997	(102)
	Brazil	1998	(103)
	Israel	1998	(104)
	Philippines	1998	(105)
	Colombia	1999	(100)
	Ecuador	1999	(100)
	Hungary	1999	(100)
	Peru	1999	(100)
	Iceland	1999	(106)
	Malaysia	2001	(100)
	Russia	2001	(100)
	Slovakia	2001	(100)
	Libya	2001	(107)
	Saudi Arabia	2001	(107)
	Denmark	2003	(108)
	Chile	2003	(109)
	Nigeria	2004	(110)
	Korea	2004	(111)
	Mexico	2005	(112)
	Kuwait	2005	(113)
	Niger	2005	(110)
	Tunisia	2006	(114)
	Lithuania	2006	(115)
	Cuba	2007	(116)
	Ethiopia	2008	(117)
	Romania	2008	(118)
	Lebanon	2008	(119)
	Iran	2008	(120)
	Pakistan	2009	(121)
	Kenya	2010	(122)
	Cameroon	2012	(123)
	Egypt	2013	(124)
	Uganda	2013	(125)
	Serbia	2015	(126)
	New Zealand	2015	(127)
<i>Candida auris</i>	Japan	2008	(128)
	Pakistan	2008	(128)
	Korea	2009	(129)
	South Africa	2012	(128)
	India	2012	(128)
	Venezuela	2012	(128)
	USA	2013	(130)
	Colombia	2013	(131)
	Kuwait	2014	(132)

	UK	2015	(133)
	Panama	2016	(134)
	Norway	2016	(129)
	Kenya	2016	(129)
	Spain	2017	(129)
	Germany	2017	(129)
<i>Candida glabrata</i>	Germany	1985	(83)
	UK	1988	(135)
	Switzerland	1990	(84)
	Ireland	1991	(136)
	USA	1993	(137)
	France	1993	(138)
	Italy	1994	(139)
	Spain	1994	(140)
	China	1996	(93)
	Japan	1996	(98)
	Chile	1996	(141)
	Greece	1996	(96)
	Lebanon	1996	(97)
	India	1997	(101)
	Netherlands	1997	(99)
	Australia	1997	(99)
	Portugal	1997	(99)
	Philippines	1998	(105)
	Israel	1998	(104)
	Iceland	1999	(106)
	Malaysia	1999	(142)
	Brazil	1999	(143)
	Taiwan	1999	(144)
	Turkey	1999	(145)
	Saudi Arabia	2001	(107)
	Argentina	2001	(146)
	Singapore	2002	(147)
	Belgium	2002	(148)
	Sweden	2003	(149)
	Denmark	2003	(108)
	Slovakia	2004	(150)
	Korea	2004	(111)
	Mexico	2005	(112)
	Kuwait	2005	(113)
	Nigeria	2005	(110)
	Canada	2005	(151)
	Lithuania	2006	(115)
	Iran	2008	(120)
	Tunisia	2009	(114)

	Kenya	2010	(122)
	Finland	2011	(152)
	Uganda	2013	(125)
	New Zealand	2015	(127)
<i>Cryptococcus gattii</i>	USA	1965	(153)
	Colombia	1989	(153)
	France	1993	(154)
	Zambia	1993	(155)
	Taiwan	1997	(156)
	Canada	1999	(153)
	India	2006	(157)
	Malaysia	2006	(158)
	Brazil	2009	(159)
	Australia	2010	(153)
	Denmark	2016	(160)
	Cameroon	2016	(161)
<i>Cryptococcus neoformans</i>	UK	1986	(162)
	USA	1992	(163)
	Spain	1994	(164)
	Rwanda	1994	(165)
	Congo	1994	(165)
	Gabon	1994	(165)
	Japan	1996	(166)
	Uganda	1996	(162)
	Brazil	1997	(167)
	Cambodia	1998	(165)
	Israel	1998	(168)
	Italy	1999	(168)
	Korea	2001	(169)
	Taiwan	2002	(170)
	Serbia	2002	(171)
	Kenya	2003	(172)
	Romania	2003	(173)
	Kenya	2003	(172)
	France	2003	(174)
	South Africa	2005	(175)
	Brazil	2006	(176)
	India	2006	(157)
	India	2006	(177)
	Malaysia	2006	(158)
	Colombia	2006	(178)
	China	2009	(179)
	Germany	2009	(180)

	Cameroon	2009	(181)
	Australia	2010	(182)
	Canada	2010	(182)
	Thailand	2011	(183)
	Argentina	2015	(184)
	Denmark	2016	(160)
Plant pathogens			
<i>Blumeriella jaapii</i>	1995	USA	(185)
<i>Botryosphaeria dothidea</i>	2000	USA	(186)
<i>Botryosphaeria theobromae</i>	2007	Brazil	(187)
<i>Botrytis cinerea</i>	1990	Israel	(188)
	1992	Germany	(189)
	1997	France	(190)
	2006	China	(191)
<i>Calonectria pauciramosa</i>	2009	Italy	(192)
<i>Calonectria polizzi</i>	2009	Italy	(192)
<i>Cercospora beticola</i>	1995	Greece	(193)
	2002	USA	(194)
	2007	Serbia	(195)
	2012	Germany	(196)
	2012	France	(196)
	2013	Italy	(196)
	2013	Switzerland	(196)
<i>Cladosporium caryigenum</i>	2003	USA	(197)
<i>Colletotrichum gloeosporioides</i>	1988	Costa Rica	(198)
	2001	Taiwan	(199)
	2003	Mexico	(200)
	2013	China	(201)

<i>Colletotrichum nymphaeae</i>	2016	USA	(202)
<i>Colletotrichum truncatum</i>	2013	China	(203)
	2016	USA	(202)
<i>Erysiphe graminis f. sp. hordeii</i>	1980	UK	(204)
	1990	Italy	(205)
	1990	Spain	(205)
	1990	Austria	(205)
	1990	Germany	(205)
	1990	Poland	(205)
	1990	Switzerland	(205)
	1990	France	(205)
	1990	Czech Republic/Slovakia	(205)
	1990	Denmark	(205)
	1991	Canada	(206)
	2014	Australia	(207)
<i>Erysiphe graminis f. sp. tritici</i>	1981	Germany	(208)
	1982	Netherlands	(209)
	1991	France	(210)
	1993	Czech Republic	(211)
	1993	Austria	(211)
	1993	Hungary	(211)
	1993	Slovakia	(211)
	1994	China	(212)
	1997	UK	(213)
	2009	Australia	(214)
	2013	USA	(215)
	2016	Belgium	(214)
	2016	Poland	(214)
<i>Exserohilum turcicum</i>	2009	USA	(216)
<i>Fusarium asiaticum</i>	2007	China	(217)

<i>Fusarium graminearum</i>	2008	China	(217)
	2008	Germany	(218)
	2010	Brazil	(219)
	2011	Italy	(218)
	2011	USA	(220)
	2014	Hungary	(221)
<i>Fusarium moniliforme</i>	2013	China	(222)
<i>Geotrichum candidum</i>	2007	USA	(223)
<i>Golovinomyces cichoracearum</i>	2002	Czech Republic	(224)
<i>Leptosphaeria maculans</i>	2013	Australia	(225)
<i>Magnaporthe grisea</i>	2017	China	(226)
<i>Monilinia fructicola</i>	1992	New Zealand	(227)
	1995	USA	(228)
	2008	Brazil	(229)
	2010	Spain	(230)
<i>Mycosphaerella fijiensis</i>	1994	Costa Rica	(231)
	2000	Cuba	(232)
	2008	Colombia	(233)
	2009	Honduras	(234)
	2009	Guatemala	(234)
	2010	Ecuador	(235)
	2010	Mexico	(236)
	2011	Dominican Republic	(237)
	2012	Philippines	(234)
	2014	Belize	(234)
	2014	Panama	(234)
	2016	Cameroon	(238)
	2016	Ivory Coast	(238)
<i>Mycosphaerella musicola</i>	2014	Australia	(234)

<i>Mycovellosiella natrassii</i>	1998	Japan	(239)
<i>Penicillium digitatum</i>	1986	USA	(240)
	1989	Argentina	(241)
	1989	Cyprus	(241)
	1989	Greece	(241)
	1989	Israel	(241)
	1989	Italy	(241)
	1989	Morocco	(241)
	1989	Spain	(241)
	1989	Uruguay	(241)
	1990	Japan	(242)
	2011	South Africa	(243)
	2011	Chile	(243)
	2011	Australia	(243)
	2013	China	(244)
<i>Parastagonospora nodorum</i>	1994	Switzerland	(245)
	2001	China	(245)
	2005	Denmark	(245)
	2005	Sweden	(245)
			(53)
<i>Penicillium italicum</i>	1983	Egypt	(246)
	1989	Morocco	(241)
	1989	Turkey	(241)
	1989	Uruguay	(241)
	1994	USA	(247)
<i>Phakopsora pachyrhizi</i>	2009	Brazil	(248)
<i>Podosphaera aphanis</i>	2006	France	(249)
<i>Pseudocercospora herpotrichoides</i> var. <i>herpotrichoides</i>	1985	France	(250)
	1986	Germany	(251)
	1986	UK	(251)

	1992	South Africa	(252)
	2000	New Zealand	(253)
	2015	Czech Republic	(254)
<i>Pseudocercospora herpotrichoides</i> var. <i>acuformis</i>	1984	Germany	(251)
	1986	UK	(251)
	1986	France	(251)
<i>Puccinia horiana</i>	1992	Netherlands	(210)
	1997	Germany	(255)
	1999	UK	(256)
<i>Puccinia striiformis</i>	1997	UK	(257)
<i>Puccinia triticina</i>	1997	France	(258)
	1997	Germany	(258)
	1997	UK	(258)
	2007	Brazil	(259)
<i>Pyrenopeziza brassicae</i>	2003	UK	(260)
	1984	New Zealand	(261)
<i>Pyrenophora teres</i>	1986	UK	(262)
	1991	USA	(263)
	1991	Germany	(263)
	1992	Canada	(264)
	1996	South Africa	(265)
	2007	Poland	(266)
	2013	Australia	(267)
	2017	France	(196)
<i>Pyrenophora tritici-repentis</i>	1990	Germany	(268)
<i>Ramularia collo-cygni</i>	2015	Germany	(207)
	2016	Denmark	(214)
	2016	Sweden	(214)
	2017	Ireland	(196)
	2017	Belgium	(196)
	2017	France	(196)

	2017	Austria	(196)
	2017	UK	(196)
<i>Rhizoctonia solani</i>	2011	USA	(269)
	2013	India	(270)
<i>Rhynchosporium commune</i>	1985	UK	(271)
	1988	New Zealand	(261)
	1995	South Africa	(272)
	1999	Switzerland	(273)
	2005	Spain	(273)
	2008	France	(271)
<i>Sclerotinia homoeocarpa</i>	1992	USA	(274)
	1994	Canada	(275)
	2001	Italy	(276)
<i>Septoria pyricola</i>	2006	Greece	(277)
<i>Sphaerotheca clandestina</i>	2005	USA	(278)
<i>Sphaerotheca fuliginea</i>	1981	Netherlands	(279)
	1982	Greece	(280)
	1982	Israel	(280)
	1982	Jordan	(280)
	1982	Spain	(280)
	1982	Syria	(280)
	1983	Norway	(279)
	1983	UK	(279)
	1986	USA	(281)
	1989	Japan	(282)
	1993	Australia	(283)
	2001	Czech Republic	(224)
	2008	South Korea	(284)
<i>Sphaerotheca mors-uvae</i>	1988	Poland	(285)
<i>Sphaerotheca pannosa</i>	1999	Israel	(286)
<i>Stagonosporopsis</i>	2013	USA	(287)

<i>caricae</i>			
	2016	Brazil	(287)
<i>Uncinula necator</i>	1988	Portugal	(288)
	1989	France	(288)
	1989	USA	(289)
	1990	Italy	(288)
	1996	Switzerland	(290)
	1996	Israel	(290)
	1996	India	(290)
	1996	Austria	(291)
	1998	South Africa	(292)
	1998	Australia	(293)
	2008	Chile	(294)
<i>Venturia inaequalis</i>	1984	Canada	(295)
	1985	Germany	(296)
	1985	France	(297)
	1986	Italy	(298)
	1988	USA	(299)
	1990	New Zealand	(300)
	2000	Czech Republic	(301)
	2001	Poland	(302)
	2002	Australia	(303)
	2007	UK	(304)
	2008	Chile	(305)
	2009	Serbia	(306)
	2010	Uruguay	(307)
	2016	Japan	(214)
<i>Venturia nashicola</i>	1995	Japan	(308)
<i>Zymoseptoria tritici</i>	1991	UK	(309)
	1992	Denmark	(310)
	1993	France	(311)
	1996	Germany	(311)
	1999	Switzerland	(312)
	2003	Ireland	(313)
	2007	Belarus	(314)
	2007	Belgium	(314)
	2007	Finland	(314)
	2007	Latvia	(314)
	2007	Norway	(314)
	2007	Poland	(314)
	2007	Sweden	(314)
	2008	Tunisia	(315)

	2009	Russia	(316)
	2009	Czech Republic	(316)
	2009	Austria	(317)
	2009	Lithuania	(318)
	2012	Ukraine	(319)
	2012	USA	(320)
	2012	Australia	(321)
	2013	New Zealand	(322)
	2014	Netherlands	(214)
	2014	Luxembourg	(214)
	2014	Estonia	(323)
	2015	Hungary	(324)

1240

1241 ¹ Year of collection of earliest resistant isolate where given (latest year in range where only
1242 multi-year pooled data are reported); otherwise, year of publication.

1243